<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer - Kunath, F - 2014 | Cochrane Library</title> <meta content="Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer - Kunath, F - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009266.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer - Kunath, F - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009266.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009266.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer" name="citation_title"/> <meta content="Frank Kunath" name="citation_author"/> <meta content="frank.kunath@uk-erlangen.de" name="citation_author_email"/> <meta content="Henrik R Grobe" name="citation_author"/> <meta content="University Medical Center Freiburg" name="citation_author_institution"/> <meta content="Gerta Rücker" name="citation_author"/> <meta content="Medical Center ‐ University of Freiburg" name="citation_author_institution"/> <meta content="Edith Motschall" name="citation_author"/> <meta content="Medical Center ‐ University of Freiburg" name="citation_author_institution"/> <meta content="Gerd Antes" name="citation_author"/> <meta content="Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg" name="citation_author_institution"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="Bernd Wullich" name="citation_author"/> <meta content="Joerg J Meerpohl" name="citation_author"/> <meta content="Medical Center ‐ University of Freiburg" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD009266.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/06/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009266.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009266.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009266.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Androgen Antagonists [adverse effects, *therapeutic use]; Anilides [adverse effects, therapeutic use]; Antineoplastic Agents, Hormonal [adverse effects, *therapeutic use]; Disease Progression; Flutamide [adverse effects, therapeutic use]; Gonadotropin‐Releasing Hormone [adverse effects, *therapeutic use]; Goserelin [adverse effects, therapeutic use]; Leuprolide [adverse effects, therapeutic use]; Medication Adherence [statistics &amp; numerical data]; Nitriles [adverse effects, therapeutic use]; Orchiectomy [*methods, mortality]; Prostatic Neoplasms [mortality, pathology, *therapy]; Randomized Controlled Trials as Topic; Tosyl Compounds [adverse effects, therapeutic use]; Triptorelin Pamoate [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009266.pub2&amp;doi=10.1002/14651858.CD009266.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="fw9sVDQH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009266\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009266\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009266.pub2",title:"Non\\u2010steroidal antiandrogen monotherapy compared with luteinising hormone\\u2013releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer",firstPublishedDate:"Jun 30, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009266.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009266.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009266.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009266.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009266.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009266.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009266.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009266.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009266.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009266.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2861 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009266.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-sec-0114"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/appendices#CD009266-sec-0119"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/table_n/CD009266StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/table_n/CD009266StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information#CD009266-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Frank Kunath</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information#CD009266-cr-0003">Henrik R Grobe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information#CD009266-cr-0004">Gerta Rücker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information#CD009266-cr-0005">Edith Motschall</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information#CD009266-cr-0006">Gerd Antes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information#CD009266-cr-0007">Philipp Dahm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information#CD009266-cr-0008">Bernd Wullich</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information#CD009266-cr-0009">Joerg J Meerpohl</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information/en#CD009266-sec-0128">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 June 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009266.pub2">https://doi.org/10.1002/14651858.CD009266.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009266-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009266-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009266-abs-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009266-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009266-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009266-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009266-abs-0001" lang="en"> <section id="CD009266-sec-0001"> <h3 class="title" id="CD009266-sec-0001">Background</h3> <p>Non‐steroidal antiandrogens and castration are the main therapy options for advanced stages of prostate cancer. However, debate regarding the value of these treatment options continues. </p> </section> <section id="CD009266-sec-0002"> <h3 class="title" id="CD009266-sec-0002">Objectives</h3> <p>To assess the effects of non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for treating advanced stages of prostate cancer. </p> </section> <section id="CD009266-sec-0003"> <h3 class="title" id="CD009266-sec-0003">Search methods</h3> <p>We searched the Cochrane Prostatic Diseases and Urologic Cancers Group Specialized Register (PROSTATE), the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Web of Science with Conference Proceedings, three trial registries and abstracts from three major conferences to 23 December 2013, together with reference lists, and contacted selected experts in the field and manufacturers. </p> </section> <section id="CD009266-sec-0004"> <h3 class="title" id="CD009266-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials comparing non‐steroidal antiandrogen monotherapy with medical or surgical castration monotherapy for men in advanced stages of prostate cancer. </p> </section> <section id="CD009266-sec-0005"> <h3 class="title" id="CD009266-sec-0005">Data collection and analysis</h3> <p>One review author screened all titles and abstracts; only citations that were clearly irrelevant were excluded at this stage. Then, two review authors independently examined full‐text reports, identified relevant studies, assessed the eligibility of studies for inclusion, assessed trial quality and extracted data. We contacted the study authors to request additional information. We used Review Manager 5 for data synthesis and used the fixed‐effect model for heterogeneity less than 50%; we used the random‐effects model for substantial or considerable heterogeneity. </p> </section> <section id="CD009266-sec-0006"> <h3 class="title" id="CD009266-sec-0006">Main results</h3> <p>Eleven studies involving 3060 randomly assigned participants were included in this review. The quality of evidence is hampered by risk of bias. Use of non‐steroidal antiandrogens decreased overall survival (hazard ratio (HR) 1.24, 95% confidence interval (CI) 1.05 to 1.48, six studies, 2712 participants) and increased clinical progression (one year: risk ratio (RR) 1.25, 95% CI 1.08 to 1.45, five studies, 2067 participants; 70 weeks: RR 1.26, 95% CI 1.08 to 1.45, six studies, 2373 participants; two years: RR 1.14, 95% CI 1.04 to 1.25, three studies, 1336 participants), as well as treatment failure (one year: RR 1.19, 95% CI 1.02 to 1.38, four studies, 1539 participants; 70 weeks: RR 1.27, 95% CI 1.05 to 1.52, five studies, 1845 participants; two years: RR 1.14, 95% CI 1.05 to 1.24, two studies, 808 participants), compared with medical or surgical castration. The quality of evidence for overall survival, clinical progression and treatment failure was rated as moderate according to GRADE. Predefined subgroup analyses showed that use of non‐steroidal antiandrogens, compared with castration, was less favourable for overall survival, clinical progression (at one year, 70 weeks, two years) and treatment failure (at one year, 70 weeks, two years) in men with metastatic disease. Use of non‐steroidal antiandrogens also increased the risk for treatment discontinuation due to adverse events (RR 1.82, 95% CI 1.13 to 2.94, eight studies, 1559 participants), including events such as breast pain (RR 22.97, 95% CI 14.79 to 35.67, eight studies, 2670 participants), gynaecomastia (RR 8.43, 95% CI 3.19 to 22.28, nine studies, 2774 participants) and asthenia (RR 1.77, 95% CI 1.36 to 2.31, five studies, 2073 participants). The risk of other adverse events, such as hot flashes (RR 0.23, 95% CI 0.19 to 0.27, nine studies, 2774 participants), haemorrhage (RR 0.07, 95% CI 0.01 to 0.54, two studies, 546 participants), nocturia (RR 0.38, 95% CI 0.20 to 0.69, one study, 480 participants), fatigue (RR 0.52, 95% CI 0.31 to 0.88, one study, 51 participants), loss of sexual interest (RR 0.50, 95% CI 0.30 to 0.83, one study, 51 participants) and urinary frequency (RR 0.22, 95% CI 0.11 to 0.47, one study, 480 participants) was decreased when non‐steroidal antiandrogens were used. The quality of evidence for breast pain, gynaecomastia and hot flashes was rated as moderate according to GRADE. The effects of non‐steroidal antiandrogens on cancer‐specific survival and biochemical progression remained unclear. </p> </section> <section id="CD009266-sec-0007"> <h3 class="title" id="CD009266-sec-0007">Authors' conclusions</h3> <p>Currently available evidence suggests that use of non‐steroidal antiandrogen monotherapy compared with medical or surgical castration monotherapy for advanced prostate cancer is less effective in terms of overall survival, clinical progression, treatment failure and treatment discontinuation due to adverse events. Evidence quality was rated as moderate according to GRADE. Further research is likely to have an important impact on results for patients with advanced but non‐metastatic prostate cancer treated with non‐steroidal antiandrogen monotherapy. However, we believe that research is likely not necessary on non‐steroidal antiandrogen monotherapy for men with metastatic prostate cancer. Only high‐quality, randomised controlled trials with long‐term follow‐up should be conducted. If further research is planned to investigate biochemical progression, studies with standardised follow‐up schedules using measurements of prostate‐specific antigen based on current guidelines should be conducted. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009266-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009266-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009266-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009266-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009266-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009266-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009266-abs-0005" lang="en"> <h3>Androgen suppression monotherapy for treatment of advanced prostate cancer</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence on the effects of androgen suppression monotherapies (non‐steroidal antiandrogens compared with medical or surgical castration monotherapy) in men with advanced prostate cancer. </p> <p><b>Background</b> </p> <p>Prostate cancer is among the top six most lethal cancers, and treatment implies a high disease burden for patients. An advanced prostate cancer has spread outside the prostate gland or has metastasised to lymph nodes, bones and/or other areas. Currently no curative therapy for advanced prostate cancer is known, although androgen suppression therapy is commonly used to treat the disease at this stage. We wanted to discover the effects of androgen suppression monotherapies in the treatment of patients in advanced stages of prostate cancer. </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to December 2013. We included 11 studies involving 3060 randomly assigned participants at advanced stages of prostate cancer. The follow‐up period of participants ranged from six months to six years. In seven studies, authors reported possible conflicts of interest. In three studies, no conflicts of interest were declared. In one study, authors reported that they had received an educational grant from the sponsor, who had no role in any aspect of analysis or data interpretation. </p> <p><b>Key results</b> </p> <p>Use of non‐steroidal antiandrogens decreased overall survival and increased clinical progression and treatment failure. Subgroup analyses showed that non‐steroidal antiandrogens, compared with castration, were less favourable for overall survival, for clinical progression and for treatment failure in men with metastatic disease. Participants receiving antiandrogens were also more likely to stop treatment as the result of side effects. The risk of suffering breast pain, enlargement of breast tissue or symptoms of physical weakness was also increased with non‐steroidal antiandrogens. The risks of feeling intense heat with sweating and rapid heartbeat and of bleeding, the need to get up in the night to urinate, loss of sexual interest, extreme tiredness and the need to urinate more often than usual were increased with castration. No difference was noted for other side effects. The effect of non‐steroidal antiandrogens on cancer‐specific survival and biochemical progression remained unclear. </p> <p><b>Quality of the evidence</b> </p> <p>Included studies were poorly conducted, and the quality of evidence was rated as moderate. This means that further research is likely to have an important impact on our confidence in the accuracy of results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009266-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009266-sec-0114"></div> <h3 class="title" id="CD009266-sec-0115">Implications for practice</h3> <section id="CD009266-sec-0115"> <p>Based on our assessment of the best available evidence, use of non‐steroidal antiandrogen monotherapy rather than medical or surgical castration monotherapy is less effective for treating men with advanced prostate cancer with respect to overall survival, clinical progression, treatment failure and treatment discontinuation due to adverse events. Some of the variation in study results may be attributable to disease stage, as subgroup analyses showed that these effects were more pronounced in men with metastatic disease. Additionally, subgroup analyses by dose showed less favourable effects regarding the non‐steroidal antiandrogen bicalutamide 50 mg daily for overall survival, clinical progression with imputed event numbers at 70 weeks and treatment failure with imputed event numbers at 70 weeks, as well as for the non‐steroidal antiandrogen bicalutamide 150 mg daily for clinical progression and treatment failure at one year, 70 weeks and two years compared with castration. However, subgroup analyses could be confounded because their results are observational in nature and contain greater uncertainty. Adverse events should be considered in both non‐steroidal antiandrogen and castration therapies. </p> </section> <h3 class="title" id="CD009266-sec-0116">Implications for research</h3> <section id="CD009266-sec-0116"> <p>The quality of evidence according to GRADE is only moderate. However, we believe that further research on non‐steroidal antiandrogen monotherapy is likely not necessary for the subgroup of men with metastatic prostate cancer. Further research is likely to have an important impact on results for the subgroup of patients with advanced but non‐metastatic prostate cancer treated with non‐steroidal antiandrogen monotherapy. Only high‐quality, randomised controlled trials with long‐term follow‐up should be conducted. If further research is planned to investigate biochemical progression, studies with standardised follow‐up schedules using measurements of PSA based on current guidelines should be conducted. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009266-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009266-sec-0029"></div> <div class="table" id="CD009266-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy for advanced prostate cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy for advanced prostate cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> men with advanced prostate cancer<br/> <b>Settings:</b> multi‐centre (9 studies) and single‐centre studies (2 studies) on outpatients<br/> <b>Intervention:</b> non‐steroidal antiandrogen monotherapy </p> <p><b>Comparison:</b> LHRH agonists or surgical castration monotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Hazard ratio/ Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Castration</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Non‐steroidal antiandrogen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> <br/> Follow‐up: median 1 to 6.3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>353 per 1000</b> <br/> (308 to 405) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.24</b> <br/> (1.05 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2712<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival was evaluated using the random‐effects model because of heterogeneity (I<sup>2</sup> = 51%). Sensitivity analyses showed comparable results. Numbers of absolute risks relate to deaths </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical progression</b> <br/> Follow‐up: median 70 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>529 per 1000</b> <br/> (453 to 608) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/> (1.08 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2373<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical progression after median 70 weeks was evaluated using the random‐effects model because of heterogeneity (I<sup>2</sup> = 64%). Sensitivity analyses showed comparable results. After imputation of event numbers: RR 1.43, 95% CI 1.19 to 1.73, I<sup>2</sup> = 0%; fixed‐effect model </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> <br/> Follow‐up: median 70 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>527 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>669 per 1000</b> <br/> (553 to 801) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.27</b> <br/> (1.05 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1845<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure after median 70 weeks was evaluated using the random‐effects model because of heterogeneity (I<sup>2</sup> = 81%). Sensitivity analyses showed comparable results. After imputation of event numbers: RR 1.21, 95% CI 1.09 to 1.35, I<sup>2</sup> = 0%; fixed‐effect model </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breast pain</b> <br/> Follow‐up: median 1 to 6.3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>397 per 1000</b> <br/> (256 to 617) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 22.97</b> <br/> (14.79 to 35.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2670<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Breast pain was evaluated using the fixed‐effect model (I<sup>2</sup> = 0%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gynaecomastia</b> <br/> Follow‐up: median 1 to 6.3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b> <br/> (142 to 989) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.43</b> <br/> (3.19 to 22.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2774<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gynaecomastia was evaluated using the random‐effects model because of heterogeneity (I<sup>2</sup> = 92%). Sensitivity analyses showed comparable results </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hot flashes</b> <br/> Follow‐up: median 1 to 6.3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> <br/> (86 to 122) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.23</b> <br/> (0.19 to 0.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2774<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hot flashes were evaluated using the fixed‐effect model (I<sup>2</sup> = 0%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>LHRH:</b> Luteinising hormone‐releasing hormone; <b>CI:</b> Confidence interval; <b>HR:</b> Hazard ratio; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for study limitations (‐1): high risk of bias: 'allocation concealment' (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); unclear risk of bias: 'random sequence generation' (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'allocation concealment' (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301;</a><a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'blinding of participants and personnel' (all included studies); 'other bias' (all included studies).<br/> <sup>2</sup>Downgraded for study limitations (‐1): high risk of bias: 'blinding of participants and personnel' (all included studies); 'blinding of outcome assessment' (all included studies); 'incomplete outcome data' (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301;</a><a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302;</a><a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>); 'selective reporting' (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>); unclear risk of bias: 'random sequence generation' (all included studies); 'allocation concealment' (all included studies); 'other bias' (all included studies).<br/> <sup>3</sup>Downgraded for study limitations (‐1): high risk of bias: 'blinding of participants and personnel' (all included studies); 'blinding of outcome assessment' (all included studies); 'incomplete outcome data' (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301;</a><a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302;</a><a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>); unclear risk of bias: 'random sequence generation' (all included studies); 'allocation concealment' (all included studies); 'other bias' (all included studies).<br/> <sup>4</sup>Downgraded for study limitations (‐1): high risk of bias: 'allocation concealment' (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'blinding of participants and personnel' (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004;</a><a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301;</a><a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302;</a><a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'blinding of outcome assessment' (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'incomplete outcome data' (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>); unclear risk of bias: 'random sequence generation' (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'allocation concealment' (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'blinding of participants and personnel' (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>); 'blinding of outcome assessment' (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>); 'other bias' (all included studies).<br/> <sup>5</sup>Downgraded for study limitations (‐1): high risk of bias: 'allocation concealment' (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'blinding of participants and personnel' (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'blinding of outcome assessment' (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'incomplete outcome data' (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>); unclear risk of bias: 'random sequence generation' (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'allocation concealment' (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'blinding of participants and personnel' (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>); 'blinding of outcome assessment' (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>); 'other bias' (all included studies).<br/> <sup>6</sup>Heterogeneity was present but might be explained by subgroup or sensitivity analyses (see <a href="#CD009266-sec-0083">Effects of interventions</a>; <a href="#CD009266-sec-0108">Quality of the evidence</a>); therefore we did not downgrade for inconsistency. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009266-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009266-sec-0030"></div> <section id="CD009266-sec-0031"> <h3 class="title" id="CD009266-sec-0031">Description of the condition</h3> <p>Prostate cancer is a frequently occurring tumour that leads to 85,200 cancer deaths per year in Europe (<a href="./references#CD009266-bbs2-0096" title="BoyleP , FerlayJ . Cancer incidence and mortality in Europe, 2004. Annals of Oncology2005;16(3):481‐8. ">Boyle 2005</a>). Worldwide, tumours of this type are associated with significant morbidity and are among the top six most lethal cancers (<a href="./references#CD009266-bbs2-0104" title="EhemanC , HenleySJ , Ballard‐BarbashR , JacobsEJ , SchymuraMJ , NooneA‐M , et al. Annual Report to the Nation on the status of cancer, 1975‐2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer2012;118(9):2338‐66. ">Eheman 2012</a>; <a href="./references#CD009266-bbs2-0108" title="FerlayJ , SoerjomataramI , ErvikM , DikshitR , EserS , MathersC , et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr (accessed 8 April 2014). ">GLOBOCAN 2012</a>); therefore, optimising therapy for prostate cancer is crucial. </p> <p>Prostate cancer is usually classified as localised disease that is limited to the prostate gland (localised, stage T1‐2, N0, M0) or more advanced disease that has spread locally outside the prostate gland (locally advanced, stage T3‐4, N0, M0), disseminated to regional lymph nodes (local to regionally advanced, stage T1‐4, N1, M0) or metastasised to bones and/or to other areas (advanced, stage T1‐4, N0‐1, M1). Localised and locally advanced prostate cancers are amenable to curative treatment. However, currently no curative therapy is known for patients at local to regionally advanced and advanced stages of prostate cancer. Androgen suppression therapy is usually recommended to treat patients at this stage of the disease (<a href="./references#CD009266-bbs2-0093" title="LoblawDA , VirgoKS , NamR , SomerfieldMR , Ben‐JosefE , MendelsonDS , et al. Initial hormonal management of androgen‐sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology2007;25(12):1596‐605. ">ASCO 2007</a>; <a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>). </p> </section> <section id="CD009266-sec-0032"> <h3 class="title" id="CD009266-sec-0032">Description of the intervention</h3> <p>Several different approaches to androgen suppression monotherapy can be used at advanced stages of prostate cancer, including oestrogens, bilateral orchiectomy, luteinising hormone–releasing hormone (LHRH) agonists, LHRH antagonists, antiandrogens (non‐steroidal antiandrogens and steroidal antiandrogens) and 5‐alpha reductase inhibitors. </p> <p>Oestrogens were among the first drugs used to treat patients at advanced stages of prostate cancer. They act through negative hormonal feedback. However, their side effects, even at low doses, are significantly greater than those observed with surgical castration. Therefore, their use is no longer recommended under current guidelines (<a href="./references#CD009266-bbs2-0093" title="LoblawDA , VirgoKS , NamR , SomerfieldMR , Ben‐JosefE , MendelsonDS , et al. Initial hormonal management of androgen‐sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology2007;25(12):1596‐605. ">ASCO 2007</a>; <a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>). </p> <p>Surgical castration removes the source of testicular androgen production and can be performed totally (bilateral orchiectomy) or by a subcapsular technique (preservation of tunica albuginea and epididymis). This intervention has been effectively used for decades, and current guidelines still consider it to be the 'gold standard' (<a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>). However, it is irreversible and might cause psychological distress. </p> <p>LHRH agonists (e.g. leuprorelin, goserelin, buserelin, triptorelin) have been found to be as effective as surgical castration via orchiectomy, and no difference in overall survival has been reported among the different LHRH agonists (<a href="./references#CD009266-bbs2-0135" title="SeidenfeldJ , SamsonDJ , HasselbladV , AronsonN , AlbertsenPC , BennettCL , et al. Single‐therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta‐analysis. Annals of Internal Medicine2000;132(7):566‐77. ">Seidenfeld 2000</a>). These medications are recommended as standard initial treatment options for advanced stages of prostate cancer (<a href="./references#CD009266-bbs2-0093" title="LoblawDA , VirgoKS , NamR , SomerfieldMR , Ben‐JosefE , MendelsonDS , et al. Initial hormonal management of androgen‐sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology2007;25(12):1596‐605. ">ASCO 2007</a>; <a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>). </p> <p>LHRH antagonists are newer agents. They block hormonal effects at the pituitary gland. Whether they provide advantages over LHRH agonists has not yet been determined (<a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>). </p> <p>Antiandrogens are classified as non‐steroidal (e.g. bicalutamide, flutamide, nilutamide) or steroidal antiandrogens (e.g. cyproterone acetate). Non‐steroidal antiandrogens are mentioned in current guidelines as an alternative to medical or surgical castration in selected patients with non‐metastatic prostate cancer (<a href="./references#CD009266-bbs2-0093" title="LoblawDA , VirgoKS , NamR , SomerfieldMR , Ben‐JosefE , MendelsonDS , et al. Initial hormonal management of androgen‐sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology2007;25(12):1596‐605. ">ASCO 2007</a>; <a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>). </p> <p>5‐alpha reductase inhibitors also have antiandrogenic activity. This form of androgen manipulation has a potential role in prevention and treatment of prostate cancer (<a href="./references#CD009266-bbs2-0094" title="AzzouniF ,  MohlerJ . Role of 5α‐reductase inhibitors in prostate cancer prevention and treatment. Urology2012;79(6):1197‐205. ">Azzouni 2012</a>). Antiandrogens combined with 5‐alpha reductase inhibitors for the treatment of biochemical disease recurrence after local therapy might be a therapeutic option (<a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>), but discussions on this topic are still controversial. </p> <p>Oestrogens, LHRH antagonists, steroidal antiandrogens and 5‐alpha reductase inhibitors are not part of this review and will not be discussed further. This systematic review focuses on the effectiveness of non‐steroidal antiandrogens compared with LHRH agonists or surgical castration. </p> </section> <section id="CD009266-sec-0033"> <h3 class="title" id="CD009266-sec-0033">How the intervention might work</h3> <p>All treatment modalities that reduce androgen activity are referred to as androgen suppression therapy (<a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>). Androgen suppression therapy is usually recommended for patients with advanced prostate cancer to slow down progression and to increase the chance of survival (<a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>; <a href="./references#CD009266-bbs2-0131" title="SchmittB , BennettC , SeidenfeldJ , SamsonD , WiltTJ . Maximal androgen blockade for advanced prostate cancer. Cochrane Database of Systematic Reviews1999, Issue 2. [DOI: 10.1002/14651858.CD001526] ">Schmitt 1999</a>). The androgen testosterone is essential for the growth of prostate cells; suppression of testosterone is therefore important in prostate cancer therapy. Testosterone is produced mainly in the testes but also to a lesser extent in the adrenal glands. The release of testosterone is regulated by the hypothalamic‐pituitary‐gonadal axis. Hypothalamic LHRH stimulates the pituitary gland to release luteinising hormone (LH) and follicle‐stimulating hormone (FSH). LH stimulates the testes to secrete testosterone. Testosterone is then converted to oestrogens, which contribute to negative feedback control of hypothalamic hormone secretion. This negative feedback in turn diminishes the secretion of LH, thereby reducing testicular testosterone production (<a href="./references#CD009266-bbs2-0107" title="GibbsSJ , PlowmanPN . Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Clinical Oncology1996;8(6):346‐52. ">Gibbs 1996</a>; <a href="./references#CD009266-bbs2-0119" title="HugginsC , HodgesCV . Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Journal of Urology2002;167(2 Pt 2):948‐51. ">Huggins 2002</a>). </p> <p>Antiandrogens compete with testosterone and dihydrotestosterone at the receptor level in the prostate cell nucleus and thereby inhibit prostate cancer cell growth. Because non‐steroidal antiandrogens do not affect the pituitary gland and do not block the negative feedback mechanism, testosterone levels are not affected, but testosterone is still converted to oestrogens. This provides potential benefits for sexual function, but it also stimulates gynaecomastia (<a href="./references#CD009266-bbs2-0120" title="IversenP . Antiandrogen monotherapy: indications and results. Urology2002;60(3 Suppl 1):64‐71. ">Iversen 2002</a>). </p> <p>Bilateral orchiectomy and LHRH agonists reduce testosterone to a castration level and have been used for decades. Surgical castration removes the source of testicular androgen production, which leads to a rapid reduction in testosterone. LHRH agonists stimulate the pituitary gland continuously, which leads to desensitisation of LH and testosterone secretion (medical castration). However, before the hormonal receptors are downregulated, LHRH agonists cause an initial stimulation of LH, FSH and thereby testosterone. This process is called 'testosterone flare' and can lead to potential exacerbations of clinical symptoms in metastatic disease by stimulating the growth of prostate cancer cells. Premedication with antiandrogens can be used for a few days before the start of LHRH agonist therapy to prevent flares (<a href="./references#CD009266-bbs2-0107" title="GibbsSJ , PlowmanPN . Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Clinical Oncology1996;8(6):346‐52. ">Gibbs 1996</a>). However, castration therapies do not affect adrenal secretion of testosterone. </p> </section> <section id="CD009266-sec-0034"> <h3 class="title" id="CD009266-sec-0034">Why it is important to do this review</h3> <p>A systematic review published in 2000 concluded that survival rates might be lower with non‐steroidal antiandrogens than with medical or surgical castration (<a href="./references#CD009266-bbs2-0134" title="SeidenfeldJ , SamsonDJ , AronsonN , AlbertsonPC , BayoumiAM , BennettC , et al. Relative effectiveness and cost‐effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/technology Assessment (Summary)1999; Vol. 4:1‐246. ">Seidenfeld 1999</a>; <a href="./references#CD009266-bbs2-0135" title="SeidenfeldJ , SamsonDJ , HasselbladV , AronsonN , AlbertsenPC , BennettCL , et al. Single‐therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta‐analysis. Annals of Internal Medicine2000;132(7):566‐77. ">Seidenfeld 2000</a>). However, no update of the review has been performed, and no other current evaluation of this comparison has been published. Clinical practice guidelines on androgen suppression monotherapy for advanced stages of prostate cancer support antiandrogens for selected and motivated patients with low prostate‐specific antigen (PSA) (<a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>). Non‐steroidal antiandrogens have been argued to have fewer side effects (e.g. hot flashes), and they do not affect testosterone levels. This might offer potential benefits for sexual function. However, non‐steroidal antiandrogens have other side effects; testosterone is converted to oestrogens, and this stimulates gynaecomastia (<a href="./references#CD009266-bbs2-0120" title="IversenP . Antiandrogen monotherapy: indications and results. Urology2002;60(3 Suppl 1):64‐71. ">Iversen 2002</a>). Additionally, effectiveness has been challenged, and the debate concerning the value of different treatment options, especially the comparison between non‐steroidal antiandrogens and medical or surgical castration, continues. As current guidelines are based upon older literature, there is a need to revisit the topic to update our understanding in light of more recent data. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009266-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009266-sec-0035"></div> <p>To assess the effects of non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for treating advanced stages of prostate cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009266-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009266-sec-0036"></div> <section id="CD009266-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009266-sec-0038"> <h4 class="title">Types of studies</h4> <p>We reviewed parallel‐group randomised controlled trials comparing non‐steroidal antiandrogens versus castration (surgical or medical) for advanced stages of prostate cancer. </p> </section> <section id="CD009266-sec-0039"> <h4 class="title">Types of participants</h4> <p>Studies recruiting men at advanced stages of prostate cancer who had not received prior androgen suppression therapy were eligible. We included studies evaluating men with prostate cancer that had spread locally outside the prostate gland (locally advanced, T3‐4, N0, M0), to regional lymph nodes (local to regionally advanced, T1‐4, N1, M0), to the bones or to other areas (advanced, T1‐4, N0‐1, M1), or those who had recurrent disease after local therapy. No exclusions were based on age or ethnicity. </p> </section> <section id="CD009266-sec-0040"> <h4 class="title">Types of interventions</h4> <p>For androgen suppression monotherapies, the following comparison was considered: non‐steroidal antiandrogen monotherapy versus medical or surgical castration monotherapy. </p> <p>Medical castration and surgical castration are two different treatment options that are thought to be equally effective (<a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>; <a href="./references#CD009266-bbs2-0135" title="SeidenfeldJ , SamsonDJ , HasselbladV , AronsonN , AlbertsenPC , BennettCL , et al. Single‐therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta‐analysis. Annals of Internal Medicine2000;132(7):566‐77. ">Seidenfeld 2000</a>). For this reason, we decided to include randomised trials even if they did not differentiate between medical and surgical castration. </p> <p>We defined medical castration monotherapy as androgen suppression therapy using LHRH agonists (e.g. leuprorelin, goserelin, buserelin, triptorelin). </p> <p>Bilateral surgical castration included total and subcapsular techniques.</p> <p>LHRH antagonists, oestrogen and steroidal antiandrogen monotherapies were not a topic of this review, and trials investigating these treatment options were not included in our analysis (see <a href="#CD009266-sec-0032">Description of the intervention</a>). This review did not consider maximal androgen blockade (combination therapy of antiandrogens with medical or surgical castration). However, we did not exclude trials that used antiandrogens as short‐term flare protection for up to four weeks after medical castration (see <a href="#CD009266-sec-0032">Description of the intervention</a>). </p> </section> <section id="CD009266-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD009266-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>Overall survival.</p> </section> <section id="CD009266-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009266-list-0001"> <li> <p>Cancer‐specific survival (we assessed data for cancer‐specific mortality because data for cancer‐specific survival were not available). </p> </li> <li> <p>Treatment discontinuation due to adverse events.</p> </li> <li> <p>Clinical progression (time from random assignment to progression; determined by an increase in prostatic dimension, appearance of new or increase in existing bone or extraskeletal metastases confirmed by imaging or physical examination). </p> </li> <li> <p>Biochemical progression (time from random assignment to progression; determined by an increase of more than 25% in serum PSA concentration from the nadir value on two determinations). </p> </li> <li> <p>Treatment failure (determined by death; disease progression, i.e. an increase in prostatic dimensions, appearance of new or increase in existing bone or extraskeletal metastases confirmed by imaging or physical examination; addition of other systemic therapies for prostate cancer; loss to follow‐up; refusal to begin or continue with randomly assigned therapy; or discontinuation due to adverse events or for other reasons). </p> </li> <li> <p>Adverse events, such as breast pain, pelvic pain, bone pain, back pain, headache, abdominal pain, general pain, gynaecomastia, constipation, diarrhoea, vomiting, cardiovascular events, hypertension, loss of sexual interest, asthenia, insomnia, hot flashes, night sweats, anaemia, hepatic enzyme increase, rash, pruritus, dyspnoea, infection, pharyngitis, arthritis, sinusitis, urinary tract infection, dizziness, haemorrhage, haematuria, nocturia, urinary frequency, urinary retention, oedema, anorexia, gastrointestinal disorders, loss of sexual function and lethargy, as well as serious adverse events (defined as adverse events causing death or events that are life threatening, require inpatient hospitalisation, result in persistent or significant disability/incapacity or require intervention to prevent permanent impairment or damage). </p> </li> </ol> </p> </section> </section> </section> <section id="CD009266-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>Both electronic and manual searches were conducted.</p> <section id="CD009266-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases on 26 February 2013 and updated the search on 23 December 2013: Cochrane Prostatic Diseases and Urologic Cancers Group Specialized Register (PROSTATE; 23 December 2013); Cochrane Central Register of Controlled Trials (CENTRAL) 2013, Issue 12 (part of <i>The Cochrane Library</i>); Ovid MEDLINE, In‐Process &amp; Other Non‐Indexed Citations, Daily (1946 to 23 December 2013); EMBASE via DIMDI (<a href="http://www.dimdi.de/static/en/index.html" target="_blank">www.dimdi.de/static/en/index.html</a>; 1947 to 23 December 2013); and Web of Science with Conference Proceedings (Thomson Reuters Web of Knowledge; 1945 to 23 December 2013). The search strategy was adapted for each electronic database. For the search strategies used by the review authors, see <a href="./appendices#CD009266-sec-0120">Appendix 1</a>, <a href="./appendices#CD009266-sec-0121">Appendix 2</a>, <a href="./appendices#CD009266-sec-0122">Appendix 3</a>, <a href="./appendices#CD009266-sec-0123">Appendix 4</a> and <a href="./appendices#CD009266-sec-0124">Appendix 5</a>. No language restriction was applied. </p> </section> <section id="CD009266-sec-0046"> <h4 class="title">Searching other resources</h4> <p>The reference lists of all identified articles were screened to identify additional potentially relevant citations. We contacted selected experts in the field as well as manufacturers of non‐steroidal androgen suppression drugs to request information on unpublished studies. We searched all other resources on 26 February 2013 and updated the search on 23 December 2013. </p> <p>We performed an electronic search of abstracts from three major conferences: the American Society of Clinical Oncology (ASCO; <a href="http://jco.ascopubs.org" target="_blank">jco.ascopubs.org</a>; 2004 to 23 December 2013), the European Association of Urology (EAU; <a href="http://www.uroweb.org/" target="_blank">www.uroweb.org</a>; 2004 to 23 December 2013) and the American Urological Association (AUA; <a href="http://www.jurology.com/" target="_blank">www.jurology.com/</a>; 2008 to 23 December 2013). For keywords used to search meeting abstracts, see <a href="./appendices#CD009266-sec-0125">Appendix 6</a>. </p> <p>Additionally, we searched three trial registries for completed or ongoing studies: Current Controlled Trials (ISRCTN; <a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com/</a>; last searched 23 December 2013), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>; last searched 23 December 2013) and the World Health Organization International Clinical Trials Registry Platform Search Portal (WHO ICTRP Search Portal; <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>; last searched 23 December 2013). For keywords used to search trial registries, see <a href="./appendices#CD009266-sec-0126">Appendix 7</a>. </p> </section> </section> <section id="CD009266-sec-0047"> <h3 class="title" id="CD009266-sec-0047">Data collection and analysis</h3> <section id="CD009266-sec-0048"> <h4 class="title">Selection of studies</h4> <p>For the initial search, one review author (FK) screened all titles and abstracts of records identified by the search for relevance. Only records that were clearly irrelevant were excluded at this stage (e.g. animal/in vitro research and testing). Next, two review authors (FK, HG) independently examined the full‐text reports of the remaining records, identified relevant studies and assessed the eligibility of studies for inclusion. We resolved disagreements regarding study eligibility through discussion and consensus or, if necessary, with the help of a third review author (JM). We recorded details of excluded studies and the reasons for exclusion. One review author (FK) performed the search update, which included only records published since the time of our initial search (between 26 February 2013 and 23 December 2013). Few records were published since the time of our last search, and we retrieved no reference that fitted our inclusion criteria. Therefore we performed no full‐text screening. </p> </section> <section id="CD009266-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>In addition to details related to the quality (risk of bias) of the included studies, we extracted the following types of data. </p> <p> <ol id="CD009266-list-0002"> <li> <p>Study characteristics: population characteristics, setting, detailed nature of the intervention, detailed nature of the comparator and outcomes, place of publication and date of publication. The key purpose of collecting these data was to explore the clinical heterogeneity of the included studies. </p> </li> <li> <p>Results of the included studies: We extracted the results with respect to each of the main outcomes (see <a href="#CD009266-sec-0041">Types of outcome measures</a>). We recorded the reasons why an included study did not contribute data on a particular outcome and considered the possibilities of selective reporting of the results of particular outcomes. </p> </li> </ol> </p> <p>Two review authors (FK, HG) independently extracted data using a data extraction form based on the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009266-bbs2-0117" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011b</a>). The review authors resolved disagreements by consensus or through discussion with a third review author (JM). In addition, when necessary, we contacted the original investigators. </p> </section> <section id="CD009266-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (FK, HG) independently assessed all studies using our data extraction form and followed the domain‐based evaluation as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009266-bbs2-0116" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011a</a>) to assess the following domains as low risk of bias, unclear risk of bias or high risk of bias: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias. </p> <p>We reviewed the assessments and discussed inconsistencies in the interpretation of information given and their significance for the selected studies. We resolved disagreements through discussion with a third review author (JM). In assessing the risk of bias, we did not automatically exclude any study as a result of an unclear or high risk of bias rating. </p> </section> <section id="CD009266-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed extracted data using Review Manager 5 (<a href="./references#CD009266-bbs2-0130" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">Review Manager 2012</a>). </p> <p>We extracted hazard ratios (HRs) with 95% confidence intervals (CIs) for time‐to‐event outcomes. If HRs were not given, we used indirect estimation methods (described by Parmar et al (<a href="./references#CD009266-bbs2-0126" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>) and Williamson et al (<a href="./references#CD009266-bbs2-0143" title="WilliamsonPR , SmithCT , HuttonJL , MarsonAG . Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine2002;21(22):3337‐51. ">Williamson 2002</a>)) to calculate them. If we were unable to extract these data from the study reports or to receive the necessary information from the primary investigators, we alternatively used the proportions of participants with the respective outcomes measured at certain time points to calculate risk ratios (RRs) with 95% CIs. </p> <p>We expressed results for binary outcomes as RRs with 95% CIs as measures of uncertainty.</p> </section> <section id="CD009266-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>Only randomised controlled trials were included; cluster‐randomised or cross‐over trials were excluded. </p> </section> <section id="CD009266-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the original investigators to request missing data. We analysed the data using an intention‐to‐treat (ITT) analysis. If we did not receive all required data, and if a substantial departure of people assigned to the intervention or control group was noted, we conducted best‐case and worst‐case scenarios, as proposed by <a href="./references#CD009266-bbs2-0105" title="GambleC , HollisS . Uncertainty method improved on best‐worst case analysis in a binary meta‐analysis. Journal of Clinical Epidemiology2005;58(6):579‐88. ">Gamble 2005</a> and described briefly in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 16.2.2; <a href="./references#CD009266-bbs2-0118" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011c</a>), and presented the results as sensitivity analyses. </p> </section> <section id="CD009266-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>Statistical heterogeneity was examined by using the I<sup>2</sup> statistic (<a href="./references#CD009266-bbs2-0113" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>; <a href="./references#CD009266-bbs2-0114" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.)2003;327(7414):557‐60. ">Higgins 2003</a>). Our definitions of the thresholds for interpretation of I<sup>2</sup> are consistent with the definitions presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009266-bbs2-0099" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley &amp; Sons, 2008:243‐96. ">Deeks 2008</a>): 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% substantial heterogeneity; 75% to 100% considerable heterogeneity. Clinical heterogeneity was examined by performing subgroup analyses. For details, see <a href="#CD009266-sec-0057">Subgroup analysis and investigation of heterogeneity</a> section. </p> </section> <section id="CD009266-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>To minimise the impact of possible publication bias, we conducted electronic and manual searches of multiple databases, without imposing a language restriction, to identify published and unpublished studies. We performed a funnel plot asymmetry analysis to assess possible publication bias. </p> </section> <section id="CD009266-sec-0056"> <h4 class="title">Data synthesis</h4> <p>For data synthesis, we used Review Manager 5 (<a href="./references#CD009266-bbs2-0130" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">Review Manager 2012</a>), as provided by The Cochrane Collaboration. Meta‐analyses of the data from all contributing studies were conducted using a fixed‐effect model if I<sup>2</sup> was less than 50%, and using a random‐effects model for substantial or considerable heterogeneity if I<sup>2</sup> was greater than or equal to 50% (≥ 50%). We reported results from both models. </p> </section> <section id="CD009266-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We explored the following potential sources of heterogeneity using subgroup analyses.</p> <p> <ol id="CD009266-list-0003"> <li> <p>Disease stage: non‐metastatic (M0) versus metastatic (M1) disease.</p> </li> <li> <p>Dose of non‐steroidal antiandrogen (e.g. bicalutamide 50 mg vs bicalutamide 150 mg).</p> </li> </ol> </p> <p>We planned in advance to also evaluate a subgroup analysis regarding the effects of different control interventions (medical vs surgical castration). However, the largest included studies (<a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) permitted both control interventions but did not report results of subgroups. This involves 925 of the 1288 participants randomly assigned to the control groups (72%). We decided therefore not to evaluate subgroup analyses regarding the effects of different control interventions. </p> <p>A current guideline mentioned that non‐steroidal antiandrogen monotherapy using bicalutamide at a dose of 150 mg daily for non‐metastatic prostate cancer might be an alternative to castration for selected patients (<a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>). A narrative review suggested that non‐steroidal antiandrogen monotherapy might be an established treatment option in patients with prostate cancer, but an unexplained trend towards decreased survival should prohibit their uncritical use (<a href="./references#CD009266-bbs2-0144" title="WirthMP , HakenbergOW , FroehnerM . Antiandrogens in the treatment of prostate cancer. European Urology2007;51(2):306‐14. ">Wirth 2007</a>). Therefore for the primary outcome of overall survival, we performed post hoc subgroup analyses regarding disease stage (non‐metastatic or metastatic disease) in combination with different doses of non‐steroidal antiandrogens (bicalutamide 50, 150, 450 or 600 mg daily; <a href="./references#CD009266-fig-0004" title="">Analysis 1.1</a>). </p> <p>In accordance with the recommendation of Higgins et al, we did not perform subgroup analyses if only a few studies were included in the meta‐analysis (<a href="./references#CD009266-bbs2-0115" title="HigginsJPT , ThompsonSG . Controlling the risk of spurious findings from meta‐regression. Statistics in Medicine2004;23(11):1663‐82. ">Higgins 2004</a>). </p> </section> <section id="CD009266-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to evaluate the effects of data imputations for best‐case and worst‐case scenarios (<a href="./references#CD009266-fig-0008" title="">Analysis 1.5</a>; <a href="./references#CD009266-fig-0010" title="">Analysis 1.7</a>; <a href="./references#CD009266-fig-0012" title="">Analysis 1.9</a>). Additionally, we investigated the robustness of results through sensitivity analyses when heterogeneity was substantial or considerable (I<sup>2</sup> 50% to 90% or 75% to 100%, respectively) by excluding smaller studies from the meta‐analysis (<a href="./references#CD009266-fig-0004" title="">Analysis 1.1</a>; <a href="./references#CD009266-fig-0005" title="">Analysis 1.2</a>; <a href="./references#CD009266-fig-0007" title="">Analysis 1.4</a>; <a href="./references#CD009266-fig-0011" title="">Analysis 1.8</a>; <a href="./references#CD009266-fig-0020" title="">Analysis 1.17</a>). </p> <section id="CD009266-sec-0059"> <h5 class="title">Summary of findings table</h5> <p>We summarised the findings in a summary of findings table (<a href="./full#CD009266-tbl-0001">summary of findings Table for the main comparison</a>) in accordance with GRADE methodology (<a href="./references#CD009266-bbs2-0110" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. ">Guyatt 2011</a>; <a href="./references#CD009266-bbs2-0133" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Schünemann 2011</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009266-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009266-sec-0060"></div> <section id="CD009266-sec-0061"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD009266-sec-0135" title="">Characteristics of included studies</a> and <a href="./references#CD009266-sec-0136" title="">Characteristics of excluded studies</a>. </p> <section id="CD009266-sec-0062"> <h4 class="title">Results of the search</h4> <p>For details of the search results, see <a href="#CD009266-fig-0001">Figure 1</a>. A total of 16 articles on 11 studies were finally included in the review. None of these studies was available in abstract form only. All included studies were published in English. We did not identify ongoing studies. We also did not identify further relevant studies through the search update. </p> <div class="figure" id="CD009266-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (searched 26 February 2013; updated 23 December 2013)." data-id="CD009266-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (searched 26 February 2013; updated 23 December 2013).</p> </div> </div> </div> </section> <section id="CD009266-sec-0063"> <h4 class="title">Included studies</h4> <p>For details on the included studies, see <a href="./references#CD009266-sec-0135" title="">Characteristics of included studies</a>. </p> <p>We included 11 studies that randomly assigned 3060 participants. All of the included studies fit our inclusion criteria and provided information on study population demographics. The type of non‐steroidal antiandrogen and the doses given varied among the included studies (flutamide 250 mg three times daily: <a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; bicalutamide 50 mg daily: <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>, <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a> and <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; bicalutamide 150 mg daily: <a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>, <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>, <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>, <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>, <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a> and <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; bicalutamide 450 mg daily and 600 mg daily: <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>). Two studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>) used surgical castration, and four studies used medical castration (goserelin 10.8 mg three times monthly: <a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; triptorelin 3.75 mg monthly: <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; leuprorelin 22.5 mg every three months: <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; drug not specified: <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>). In five studies, participants could choose between medical (using goserelin) and surgical castration (<a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>). In two studies (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>), participants randomly assigned to castration also received a non‐steroidal antiandrogen for two (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>) or four weeks (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>) to prevent a flare reaction. Four studies included participants with non‐metastatic prostate cancer (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>), and four studies included participants with metastatic prostate cancer (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>). Three studies included participants with non‐metastatic or metastatic disease (<a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>). The follow‐up period of participants ranged from six months (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>) to six years (<a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>). </p> <p>In seven studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>), the trial authors reported possible conflicts of interest. In three studies (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>), no conflicts of interest were declared. The authors of only one study (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>) reported that they received an educational grant from the sponsor; however, they claimed that this sponsor had no role in any aspect of the study plan, protocol or analysis; data interpretation; or writing of the manuscript. </p> </section> <section id="CD009266-sec-0064"> <h4 class="title">Excluded studies</h4> <p><a href="#CD009266-fig-0001">Figure 1</a> and the table titled <a href="./references#CD009266-sec-0136" title="">Characteristics of excluded studies</a> provide information on the numbers of and reasons for exclusions from the review. </p> </section> </section> <section id="CD009266-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>We conducted a funnel plot asymmetry analysis for our primary outcome to assess potential publication bias (<a href="#CD009266-fig-0002">Figure 2</a>). We found no indication of bias. However, the sensitivity of this analysis to assess publication bias might be low because fewer than 10 studies were included in the meta‐analyses performed. All studies were published in peer‐reviewed publications. For details on risk of bias, see <a href="#CD009266-fig-0003">Figure 3</a> and the table titled <a href="./references#CD009266-sec-0135" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD009266-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Funnel plot: Outcome: 1.1 Overall survival, 1.1.1 Total." data-id="CD009266-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot: Outcome: 1.1 Overall survival, 1.1.1 Total.</p> </div> </div> </div> <div class="figure" id="CD009266-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009266-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009266-sec-0066"> <h4 class="title">Allocation</h4> <section id="CD009266-sec-0067"> <h5 class="title">Random sequence generation</h5> <p>Three studies (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) reported adequate sequence generation (low risk of bias). In all of the other studies, information on sequence generation was not reported or was insufficient to permit a judgement (unclear risk of bias). </p> </section> <section id="CD009266-sec-0068"> <h5 class="title">Allocation concealment</h5> <p>Only one study (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>) provided information indicating adequate allocation concealment using central random assignment (low risk of bias). One study (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) contained a high risk of bias because participant numbers were allocated sequentially as men entered the trial. No other studies reported information on allocation concealment (unclear risk of bias). </p> </section> </section> <section id="CD009266-sec-0069"> <h4 class="title">Blinding</h4> <p>We assessed risk of bias for blinding of participants and personnel and for blinding of outcome assessment on an outcome‐specific basis. </p> <section id="CD009266-sec-0070"> <h5 class="title">Blinding of participants and personnel</h5> <p>All included studies were open randomised trials that did not involve blinding of participants and/or personnel. Blinding was not feasible because of differences in the interventions, which included surgical therapy (orchiectomy), medical castration by injection (LHRH agonists) and oral medications (non‐steroidal antiandrogens). </p> <section id="CD009266-sec-0071"> <h6 class="title">Overall survival, cancer‐specific mortality, biochemical progression</h6> <p>We were uncertain to what extent outcomes such as overall survival, cancer‐specific mortality and biochemical progression were influenced by lack of blinding. We judged therefore that risk of bias regarding these outcomes for most of the included studies was unclear (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>). Two studies (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>) did not assess these outcomes (unclear risk of bias). </p> </section> <section id="CD009266-sec-0072"> <h6 class="title">Clinical progression, treatment failure, treatment discontinuation due to adverse events, adverse events </h6> <p>Outcomes such as clinical progression, treatment failure, treatment discontinuation due to adverse events and adverse events could be influenced by lack of blinding. These outcomes therefore present a high risk of bias in most of the included studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>). Risk of bias was unclear for one study (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>). The original investigators responded that "subjects and study investigators were blinded to treatment assignment." However, the method of blinding bicalutamide 150 mg by mouth daily for 12 months compared with leuprorelin three‐month depot (22.5 mg intramuscularly every three months) for treatment discontinuation due to adverse events and adverse events remained unclear (unclear risk of bias). </p> </section> </section> <section id="CD009266-sec-0073"> <h5 class="title">Blinding of outcome assessment</h5> <section id="CD009266-sec-0074"> <h6 class="title">Overall survival, cancer‐specific mortality, biochemical progression</h6> <p>In all studies, no blinding was provided or blinding was not reported. However, we judged that it was not likely that outcome assessments for overall survival, cancer‐specific mortality and biochemical progression were influenced by lack of blinding (low risk of bias). Two studies (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>) did not assess these outcomes (unclear risk of bias). </p> </section> <section id="CD009266-sec-0075"> <h6 class="title">Clinical progression, treatment failure, treatment discontinuation due to adverse events, adverse events </h6> <p>We judged that for most studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) it was likely that outcome assessments of clinical progression, treatment failure, treatment discontinuation due to adverse events and adverse events were influenced by lack of blinding. For one study (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>), the original investigators responded that blinding was performed ("subjects and study investigators were blinded to treatment assignment"). However, blinding of outcome assessments for treatment discontinuation due to adverse events and adverse events remained unclear (unclear risk of bias). </p> </section> </section> </section> <section id="CD009266-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed risk of bias for incomplete outcome data on an outcome‐specific basis.</p> <section id="CD009266-sec-0077"> <h5 class="title">Overall survival, cancer‐specific mortality</h5> <p>Five studies (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>) were judged to report adequate information leading to low risk of attrition bias. In the study published by Tyrrell et al, the proportion of missing outcomes might not have had a clinically relevant impact on the intervention effect estimate, leading to low risk of bias (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>). Boccon‐Gibod et al reported data on overall survival incompletely (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>). Therefore risk of bias regarding overall survival was high. Four studies (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>) did not measure/report these outcomes (unclear risk of bias). </p> </section> <section id="CD009266-sec-0078"> <h5 class="title">Treatment discontinuation due to adverse events, adverse events</h5> <p>Three studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>) were judged to report adequate information leading to low risk of attrition bias. In four studies, the proportion of missing outcomes might not have had a clinically relevant impact on the intervention effect estimate, leading to low risk of bias (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>). One study (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>) did not measure/report these outcomes (unclear risk of bias). Three studies (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>) present high risk of attrition bias. These studies reported data on an 'as‐treated' analysis with a high rate of dropout from the intervention assigned at randomisation. </p> </section> <section id="CD009266-sec-0079"> <h5 class="title">Clinical progression, biochemical progression</h5> <p>Two studies (<a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>) were judged to report adequate information leading to low risk of attrition bias. Five studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>) present high risk of attrition bias. These studies reported data on an 'as‐treated' analysis with a high rate of dropout from the intervention group. Two studies (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>) did not measure/report these outcomes (unclear risk of bias). In two studies, the proportion of missing outcomes might not have had a clinically relevant impact on the intervention effect estimate, leading to low risk of bias (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>). </p> </section> <section id="CD009266-sec-0080"> <h5 class="title">Treatment failure</h5> <p>Two studies (<a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>) were judged to report adequate information, leading to low risk of attrition bias. Four studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>) were judged as having high risk of attrition bias. These studies reported data on an 'as‐treated' analysis with a high rate of dropout from the intervention group. One study (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>) provided an outcome definition for treatment failure in the report but did not report any data for this outcome (high risk of bias). Four studies (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) did not measure/report this outcome (unclear risk of bias). </p> </section> </section> <section id="CD009266-sec-0081"> <h4 class="title">Selective reporting</h4> <p>Three studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>) had a high risk of reporting bias. Boccon‐Gibod et al reported incomplete data on overall survival at 69 months. They reported only "identical" survival in both groups, which was irrespective of the second‐line treatment given (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>). Thus, their study could not be entered into the meta‐analysis. Dockery et al reported data on treatment discontinuation due to adverse events but did not report any data concerning individual adverse events (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>), and Sciarra et al did not report data on adverse events, treatment discontinuation due to adverse events or treatment failure (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>). We expected that these outcomes would be reported for such studies. We did not identify study protocols with adequate information on primary or secondary outcomes for all other studies; however, published reports included all of the expected outcomes. </p> </section> <section id="CD009266-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <p>In seven studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>), the trial authors reported possible conflicts of interest. In three studies (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>), no conflicts of interest were declared. The authors of only one study (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>) reported that they received an educational grant from the sponsor; however, they claimed that this sponsor had no role in any aspect of the study plan, protocol or analysis; data interpretation; or writing of the manuscript. Potential conflicts of interest may exist in any study, but we believe that in itself, this is not a reason for high risk of bias. Therefore, the risk of bias remains unclear for all studies. </p> </section> </section> <section id="CD009266-sec-0083"> <h3 class="title" id="CD009266-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD009266-tbl-0001"><b>Summary of findings for the main comparison</b> Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy for advanced prostate cancer</a> </p> <section id="CD009266-sec-0084"> <h4 class="title">Overall survival</h4> <p>Of the 11 included studies, six studies (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) involving 2712 randomly assigned participants measured overall survival. The quality of evidence for this outcome was moderate (<a href="./full#CD009266-tbl-0001">summary of findings Table for the main comparison</a>). One study (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>) reported incomplete data and therefore could not be entered into the meta‐analysis. Overall survival was significantly decreased when non‐steroidal antiandrogens were used as opposed to castration (HR 1.24, 95% CI 1.10 to 1.40, fixed‐effect model; not shown). A random‐effects model for heterogeneity (I<sup>2</sup> = 51%) still revealed a significant result (HR 1.24, 95% CI 1.05 to 1.48, 2712 participants; <a href="./references#CD009266-fig-0004" title="">Analysis 1.1</a>). We performed a sensitivity analysis because heterogeneity was noted (I<sup>2</sup> = 51%). After exclusion of the smallest study (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>), results still showed significant differences with lower heterogeneity (HR 1.31, 95% CI 1.12 to 1.53, I<sup>2</sup> = 33%; not shown). </p> <section id="CD009266-sec-0085"> <h5 class="title">Subgroup: disease stage</h5> <p>A meta‐analysis of three studies (<a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) on non‐metastatic disease showed no significant difference in overall survival between non‐steroidal antiandrogens and castration (HR 1.00, 95% CI 0.79 to 1.26, 608 participants; <a href="./references#CD009266-fig-0004" title="">Analysis 1.1</a>). However, a meta‐analysis of six studies (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) showed that overall survival was significantly decreased with non‐steroidal antiandrogens in participants with metastatic disease when compared with castration (HR 1.34, 95% CI 1.14 to 1.57, 2103 participants; <a href="./references#CD009266-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD009266-sec-0086"> <h5 class="title">Subgroup: dose of non‐steroidal antiandrogen</h5> <p>The non‐steroidal antiandrogen bicalutamide given in doses of 50 mg daily or 150 mg daily significantly decreased overall survival when compared with castration using the fixed‐effect model (bicalutamide 50 mg daily: HR 1.45, 95% CI 1.20 to 1.74, 1196 participants; bicalutamide 150 mg daily: HR 1.19, 95% CI 1.00 to 1.41, 1288 participants; not shown). However, the random‐effects model showed that bicalutamide 50 mg daily still significantly decreased overall survival (HR 1.45, 95% CI 1.19 to 1.75, 1196 participants), although the effect was compatible with benefit or harm when bicalutamide 150 mg daily was used (HR 1.18, 95% CI 0.96 to 1.45, 1288 participants; <a href="./references#CD009266-fig-0004" title="">Analysis 1.1</a>). No significant difference was noted between high‐dose bicalutamide (450 mg daily or 600 mg daily) and castration (HR 0.88, 95% CI 0.62 to 1.25, 228 participants; <a href="./references#CD009266-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD009266-sec-0087"> <h5 class="title">Subgroup (post hoc analysis): non‐metastatic disease and dose of non‐steroidal antiandrogen</h5> <p>No significant difference was found between non‐steroidal antiandrogens (bicalutamide 150 mg daily compared with 450 mg daily or 600 mg daily) and castration in participants with non‐metastatic prostate cancer (<a href="./references#CD009266-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD009266-sec-0088"> <h5 class="title">Subgroup (post hoc analysis): metastatic disease and dose of non‐steroidal antiandrogen</h5> <p>The non‐steroidal antiandrogen bicalutamide given in doses of 50 mg daily or 150 mg daily decreased overall survival in participants with metastatic disease when compared with castration (bicalutamide 50 mg daily: HR 1.45, 95% CI 1.19 to 1.75, 1196 participants; bicalutamide 150 mg daily: HR 1.30, 95% CI 1.04 to 1.63, 808 participants; <a href="./references#CD009266-fig-0004" title="">Analysis 1.1</a>). No significant difference was found between high‐dose bicalutamide (450 mg daily or 600 mg daily) and castration in participants with metastatic disease (HR 0.91, 95% CI 0.56 to 1.48, 99 participants; <a href="./references#CD009266-fig-0004" title="">Analysis 1.1</a>). </p> </section> </section> <section id="CD009266-sec-0089"> <h4 class="title">Cancer‐specific mortality</h4> <p>We presented data for cancer‐specific mortality in place of cancer‐specific survival based on availability of data in the included studies. Three studies (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) involving 904 randomly assigned participants provided data on cancer‐specific mortality. Non‐steroidal antiandrogens probably increased cancer‐specific mortality when compared with castration (RR 1.26, 95% CI 1.00 to 1.59, fixed‐effect model; not shown). However, this difference was no longer statistically significant when a random‐effects model was applied as the result of heterogeneity (I<sup>2</sup> = 67%, RR 1.32, 95% CI 0.86 to 2.05, 904 participants; <a href="./references#CD009266-fig-0005" title="">Analysis 1.2</a>). We performed a sensitivity analysis because heterogeneity was noted (I<sup>2</sup> = 67%). After the smallest study had been excluded (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>), results were still comparable but heterogeneity was greater (RR 1.63, 95% CI 0.71 to 3.73, I<sup>2</sup> = 79%; not shown). The included studies reported cancer‐specific mortality based on different follow‐up periods (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a> and <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>: after a minimum 12 months of follow‐up; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>: after a median of five years of follow‐up). Analysis of the different follow‐up periods showed that non‐steroidal antiandrogens might increase cancer‐specific mortality after a minimum of 12 months when compared with castration (RR 1.43, 95% CI 1.05 to 1.95, fixed‐effect model; not shown). However, this difference was no longer significant after a random‐effects model was applied because of heterogeneity (RR 1.63, 95% CI 0.71 to 3.73, 680 participants, I<sup>2</sup> = 79%; <a href="./references#CD009266-fig-0005" title="">Analysis 1.2</a>). We performed a sensitivity analysis because heterogeneity was present (I<sup>2</sup> = 79%). After the smaller of the two included studies had been excluded (<a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>), results of <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a> showed a significant difference (RR 2.60, 95% CI 1.30 to 5.07; not shown). No difference was found between these therapies after a median of five years (RR 1.04, 95% CI 0.73 to 1.47, 224 participants; <a href="./references#CD009266-fig-0005" title="">Analysis 1.2</a>). The overall effect of non‐steroidal antiandrogens on cancer‐specific mortality and even more on cancer‐specific survival therefore remains unclear. </p> <section id="CD009266-sec-0090"> <h5 class="title">Subgroup: disease stage</h5> <p>We did not perform subgroup analyses because very few studies were included for this outcome for which results were reported after different follow‐up periods. The conduct and presentation of meta‐analyses therefore did not seem appropriate. </p> </section> <section id="CD009266-sec-0091"> <h5 class="title">Subgroup: dose of non‐steroidal antiandrogen</h5> <p>We did not perform subgroup analyses because very few studies were included for this outcome for which results were reported after different follow‐up periods. The conduct and presentation of meta‐analyses therefore did not seem appropriate. </p> </section> </section> <section id="CD009266-sec-0092"> <h4 class="title">Treatment discontinuation due to adverse events</h4> <p>Eight studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) involving 1559 randomly assigned participants reported data on treatment discontinuation due to adverse events. Non‐steroidal antiandrogens significantly increased the rate of withdrawal due to adverse events (RR 1.82, 95% CI 1.13 to 2.94, 1559 participants; <a href="./references#CD009266-fig-0006" title="">Analysis 1.3</a>). </p> <p>Two studies (<a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>) provided incomplete data on treatment discontinuation due to adverse events; thus, the data from these studies could not be included in the meta‐analysis. The trial authors reported that after 6.3 years, 4.1% of participants with non‐metastatic disease treated with bicalutamide (n = 314) were withdrawn; 1.3% of these withdrawals were due to breast pain and/or gynaecomastia (<a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>). They reported no data for participants treated with castration. Two studies (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) did not specify the adverse events that led to discontinuation, and four studies (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>) provided only partial information on adverse events. Smith et al reported that two participants in the leuprorelin group discontinued treatment early as the result of adverse events such as hot flashes and fatigue (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>). Additionally, treatment with bicalutamide was interrupted in one participant for three months because of elevated liver enzymes (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>). In the study conducted by Sieber et al, five of nine participants who withdrew from the study in the bicalutamide group discontinued treatment as the result of asthenia (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>). In another study, four participants discontinued treatment because of adverse events; two participants withdrew because of impotence (one in each group for bicalutamide and castration) and two withdrew because of a skin reaction (both in the bicalutamide group) (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>). In <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>, six participants discontinued treatment (three with rash and one with constipation), and in <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>, three participants withdrew from the study (in the group treated with bicalutamide, one withdrew because of gynaecomastia and back pain; in the group treated with castration, one withdrew because of severe hot flashes). Boccon‐Gibod et al reported that four participants discontinued therapy; two were suffering from nausea or vomiting, one reported diarrhoea and another showed an increase in hepatic enzymes before discontinuing therapy (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>). </p> <section id="CD009266-sec-0093"> <h5 class="title">Subgroup: disease stage</h5> <p>The subgroup analysis included seven studies: three studies (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>) including participants with non‐metastatic disease, and four studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>) including participants with metastatic disease. No significant difference was found between non‐steroidal antiandrogens and castration for participants with non‐metastatic (RR 1.47, 95% CI 0.66 to 3.28, 194 participants) or metastatic disease (RR 1.39, 95% CI 0.54 to 3.54, 1141 participants; <a href="./references#CD009266-fig-0006" title="">Analysis 1.3</a>). Data reported by Tyrrell et al could not be included into this analysis because they were not reported for subgroups of participants on the basis of disease stage (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>). </p> </section> <section id="CD009266-sec-0094"> <h5 class="title">Subgroup: dose of non‐steroidal antiandrogen</h5> <p>One study evaluated the non‐steroidal antiandrogen flutamide 250 mg three times daily (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>), three studies evaluated the non‐steroidal antiandrogen bicalutamide 50 mg daily (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>), three studies evaluated bicalutamide 150 mg daily (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>) and one study evaluated bicalutamide 450 mg daily and 600 mg daily (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>). No significant differences were found for bicalutamide 50 mg daily, bicalutamide 150 mg daily or flutamide 250 mg three times daily (<a href="./references#CD009266-fig-0006" title="">Analysis 1.3</a>). However, the numbers of treatment discontinuations due to adverse events were significantly increased when bicalutamide 450 mg daily was used (RR 2.66, 95% CI 1.17 to 6.01, 182 participants). No significant differences were found between bicalutamide 600 mg daily and castration (RR 2.45, 95% CI 0.95 to 6.31, 132 participants; <a href="./references#CD009266-fig-0006" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD009266-sec-0095"> <h4 class="title">Clinical progression</h4> <p>Seven studies (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) involving 2591 randomly assigned participants were included in the meta‐analyses for clinical progression. For the definitions of clinical progression, see the <a href="./references#CD009266-sec-0135" title="">Characteristics of included studies</a> table. Two studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>) reported data on an outcome they referred to as “clinical progression.” However, we included the data in an analysis of biochemical progression because the definition provided in the reports was consistent with our previously established definition of biochemical progression. Non‐steroidal antiandrogens significantly increased clinical progression at one year, at 70 weeks and at two years when compared with castration, but no significant differences were found at three, four or five years when the fixed‐effect model was used (at one year: RR 1.27, 95% CI 1.14 to 1.41, 2067 participants; at 70 weeks: RR 1.27, 95% CI 1.16 to 1.38, 2373 participants; at two years: RR 1.13, 95% CI 1.03 to 1.24, 1336 participants; at three years: RR 1.04, 95% CI 0.87 to 1.23, 480 participants; at four years: RR 1.07, 95% CI 0.91 to 1.26, 480 participants; at five years: RR 0.96, 95% CI 0.87 to 1.06, 698 participants; not shown). The random‐effects model due to heterogeneity (I<sup>2</sup> = 64%) at 70 weeks still showed comparable results (at one year: RR 1.25, 95% CI 1.08 to 1.45, 2067 participants; at 70 weeks: RR 1.26, 95% CI 1.08 to 1.45, 2373 participants; at two years: RR 1.14, 95% CI 1.04 to 1.25, 1336 participants; at three years: RR 1.04, 95% CI 0.87 to 1.23, 480 participants; at four years: RR 1.07, 95% CI 0.91 to 1.26, 480 participants; at five years: RR 0.96, 95% CI 0.88 to 1.06, 698 participants; <a href="./references#CD009266-fig-0007" title="">Analysis 1.4</a>). We performed a sensitivity analysis for clinical progression at 70 weeks because we noted heterogeneity (I<sup>2</sup> = 64%). After the smallest study had been excluded (<a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>), results still showed significant differences with lower heterogeneity (RR 1.33, 95% CI 1.19 to 1.48, I<sup>2</sup> = 13%; not shown). Five studies (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) did not report ITT analysis data, but findings were summarised instead according to treatment received. An analysis that considered data imputations for the best‐case and worst‐case scenarios still showed significant results at one year, 70 weeks and two years but not at five years (<a href="./references#CD009266-fig-0008" title="">Analysis 1.5</a>). This analysis involved 2771 randomly assigned participants. The quality of evidence for clinical progression was moderate (<a href="./full#CD009266-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD009266-sec-0096"> <h5 class="title">Subgroup: disease stage</h5> <p>No significant differences were found between non‐steroidal antiandrogens and castration for participants with non‐metastatic disease at all evaluated time points (<a href="./references#CD009266-fig-0007" title="">Analysis 1.4</a>). An analysis considering data imputations for the best‐case and worst‐case scenarios showed comparable results (<a href="./references#CD009266-fig-0008" title="">Analysis 1.5</a>). Five studies were included in the subgroup analysis of participants with metastatic disease (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>). Clinical progression at one year (RR 1.25, 95% CI 1.05 to 1.49, I<sup>2</sup> = 64%, 1539 participants), at 70 weeks (RR 1.27, 95% CI 1.07 to 1.51, I<sup>2</sup> = 74%, 1845 participants) and at two years (RR 1.17, 95% CI 1.05 to 1.29, 808 participants) increased with non‐steroidal antiandrogens when compared with castration in participants with metastatic disease (<a href="./references#CD009266-fig-0007" title="">Analysis 1.4</a>). We performed sensitivity analyses for clinical progression at one year and at 70 weeks because heterogeneity was present. After the smallest study had been excluded (<a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>), results still showed significant differences with lower heterogeneity (at one year: RR 1.35, 95% CI 1.13 to 1.61, I<sup>2</sup> = 42%; at 70 weeks: RR 1.35, 95% CI 1.18 to 1.55, I<sup>2</sup> = 34%; not shown). The results remained significant after an analysis was performed by considering data imputations for best‐case and worst‐case scenarios (<a href="./references#CD009266-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD009266-sec-0097"> <h5 class="title">Subgroup: dose of non‐steroidal antiandrogen</h5> <p>The non‐steroidal antiandrogen bicalutamide at a dose of 50 mg daily showed no significant difference when compared with castration (at one year: RR 1.27, 95% CI 0.91 to 1.76, I<sup>2</sup> = 83%, 731 participants; at 70 weeks: RR 1.30, 95% CI 0.99 to 1.71, 1037 participants, I<sup>2</sup> = 84%; <a href="./references#CD009266-fig-0007" title="">Analysis 1.4</a>). We performed sensitivity analyses because heterogeneity was present. After the smallest study had been excluded (<a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>), results showed significant differences with lower heterogeneity (at one year: RR 1.49, 95% CI 1.21 to 1.85; at 70 weeks: RR 1.47, 95% CI 1.26 to 1.72, I<sup>2</sup> = 0%; not shown). The analysis considering data imputations for best‐case and worst‐case scenarios showed a significant increase in clinical progression with bicalutamide 50 mg daily at 70 weeks (RR 1.40, 95% CI 1.04 to 1.88, 1196 participants), but no difference was found at one year (<a href="./references#CD009266-fig-0008" title="">Analysis 1.5</a>). The non‐steroidal antiandrogen bicalutamide at a dose of 150 mg daily might increase clinical progression at one year (RR 1.25, 95% CI 1.07 to 1.46, 1336 participants), at 70 weeks (RR 1.22, 95% CI 1.07 to 1.39, 1336 participants) or at two years (RR 1.14, 95% CI 1.04 to 1.25, 1336 participants), but no differences were noted when compared with castration at three, four or five years (<a href="./references#CD009266-fig-0007" title="">Analysis 1.4</a>). An analysis considering data imputations for best‐case and worst‐case scenarios showed comparable results (<a href="./references#CD009266-fig-0008" title="">Analysis 1.5</a>). No significant differences were found between high‐dose bicalutamide (450 mg daily or 600 mg daily) and castration at five years. </p> </section> </section> <section id="CD009266-sec-0098"> <h4 class="title">Biochemical progression</h4> <p>Three studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>) involving 185 randomly assigned participants were included in the analysis of biochemical progression. For the definitions of biochemical progression in included studies, see the <a href="./references#CD009266-sec-0135" title="">Characteristics of included studies</a> table. The analysis considering data imputations for best‐case and worst‐case scenarios involved 214 randomly assigned participants. No significant differences were found between the non‐steroidal antiandrogen and castration groups at any of the evaluated time points (<a href="./references#CD009266-fig-0009" title="">Analysis 1.6</a>; <a href="./references#CD009266-fig-0010" title="">Analysis 1.7</a>). The study conducted by Smith et al was not designed to evaluate clinical cancer outcomes including clinical or biochemical progression (for details, see <a href="./references#CD009266-sec-0135" title="">Characteristics of included studies</a>). The overall effect on biochemical progression therefore remains unclear. </p> <section id="CD009266-sec-0099"> <h5 class="title">Subgroup: disease stage</h5> <p>We did not perform subgroup analyses because very few studies were included for this outcome for which results were reported after different follow‐up periods. The conduct and presentation of meta‐analyses therefore did not seem appropriate. </p> </section> <section id="CD009266-sec-0100"> <h5 class="title">Subgroup: dose of non‐steroidal antiandrogen</h5> <p>We did not perform subgroup analyses because very few studies were included for this outcome for which results were reported after different follow‐up periods. The conduct and presentation of meta‐analyses therefore did not seem appropriate. </p> </section> </section> <section id="CD009266-sec-0101"> <h4 class="title">Treatment failure</h4> <p>Six studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>) involving 2411 randomly assigned participants reported data on treatment failure. For the definition of treatment failure, see the <a href="./references#CD009266-sec-0135" title="">Characteristics of included studies</a> table. Non‐steroidal antiandrogens increased treatment failure at one year, at 70 weeks and at two years, but no difference was found at three or four years (<a href="./references#CD009266-fig-0011" title="">Analysis 1.8</a>). The random‐effects model for heterogeneity revealed significant results (at one year: I<sup>2</sup> = 63%, RR 1.19, 95% CI 1.02 to 1.38, 1539 participants; at 70 weeks: I<sup>2</sup> = 81%, RR 1.27, 95% CI 1.05 to 1.52, 1845 participants; at two years: RR 1.14, 95% CI 1.05 to 1.24, 808 participants; <a href="./references#CD009266-fig-0011" title="">Analysis 1.8</a>). We performed sensitivity analyses because heterogeneity was present. After the smallest study had been excluded (<a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>), results still showed significant differences with lower heterogeneity (at one year: RR 1.26, 95% CI 1.08 to 1.47, I<sup>2</sup> = 53%; at 70 weeks: RR 1.36, 95% CI 1.14 to 1.62, I<sup>2</sup> = 69%; not shown). An analysis considering data imputations for best‐case and worst‐case scenarios showed comparable results (<a href="./references#CD009266-fig-0012" title="">Analysis 1.9</a>). This analysis involved 2004 randomly assigned participants. The quality of evidence for treatment failure was moderate (<a href="./full#CD009266-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD009266-sec-0102"> <h5 class="title">Subgroup: disease stage</h5> <p>The subgroup analysis for non‐metastatic prostate cancer included two studies (<a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>) and showed no significant differences between non‐steroidal antiandrogens and castration at four years (RR 1.04, 95% CI 0.93 to 1.16, 480 participants; <a href="./references#CD009266-fig-0011" title="">Analysis 1.8</a>). For participants with metastatic prostate cancer, non‐steroidal antiandrogens increased treatment failure at one year (RR 1.19, 95% CI 1.02 to 1.38, I<sup>2</sup> = 63%, 1539 participants), at 70 weeks (RR 1.27, 95% CI 1.05 to 1.52, I<sup>2</sup> = 81%, 1845 participants) and at two years (RR 1.14, 95% CI 1.05 to 1.24, 808 participants). We performed sensitivity analyses for treatment failure at one year and at 70 weeks because heterogeneity was present. After the smallest study had been excluded (<a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>), results still showed significant differences with lower heterogeneity (at one year: RR 1.26, 95% CI 1.08 to 1.47, I<sup>2</sup> = 53%; at 70 weeks: RR 1.36, 95% CI 1.14 to 1.62, I<sup>2</sup> = 69%; not shown). No significant difference was found at three years (<a href="./references#CD009266-fig-0011" title="">Analysis 1.8</a>). An analysis considering data imputations for best‐case and worst‐case scenarios revealed comparable results (<a href="./references#CD009266-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD009266-sec-0103"> <h5 class="title">Subgroup: dose of non‐steroidal antiandrogen</h5> <p>No significant differences were found between the non‐steroidal antiandrogen bicalutamide at a dose of 50 mg daily and castration at any of the time points assessed using the random‐effects model for heterogeneity (<a href="./references#CD009266-fig-0011" title="">Analysis 1.8</a>). However, the analysis considering data imputations for best‐case and worst‐case scenarios showed that without heterogeneity, bicalutamide at 50 mg daily significantly increased treatment failure at one year and at 70 weeks (<a href="./references#CD009266-fig-0012" title="">Analysis 1.9</a>). Additionally, the non‐steroidal antiandrogen bicalutamide at a dose of 150 mg daily significantly increased treatment failure at one year (RR 1.17, 95% CI 1.01 to 1.35, 808 participants), at 70 weeks (RR 1.18, 95% CI 1.05 to 1.34, 808 participants) and at two years (RR 1.14, 95% CI 1.05 to 1.24, 808 participants). No difference was found at four years (<a href="./references#CD009266-fig-0011" title="">Analysis 1.8</a>; <a href="./references#CD009266-fig-0012" title="">Analysis 1.9</a>). One study (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>) assessed the non‐steroidal antiandrogen flutamide at a dose of 250 mg three times daily compared with castration and showed no significant differences at three years (<a href="./references#CD009266-fig-0011" title="">Analysis 1.8</a>; <a href="./references#CD009266-fig-0012" title="">Analysis 1.9</a>). </p> </section> </section> <section id="CD009266-sec-0104"> <h4 class="title">Adverse events</h4> <p>Nine studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) reported data on adverse events associated with treatment with non‐steroidal antiandrogens compared with castration. </p> <p>Non‐steroidal antiandrogens were associated with a significantly increased occurrence of breast pain (RR 22.97, 95% CI 14.79 to 35.67, 2670 participants; <a href="./references#CD009266-fig-0013" title="">Analysis 1.10</a>). Subgroup analyses showed that this was also evident for bicalutamide at a dose of 50 mg, 150 mg, 450 mg or 600 mg daily (<a href="./references#CD009266-fig-0013" title="">Analysis 1.10</a>). </p> <p>The risk of suffering gynaecomastia was increased with non‐steroidal antiandrogens (RR 8.43, 95% CI 3.19 to 22.28, 2774 participants; <a href="./references#CD009266-fig-0020" title="">Analysis 1.17</a>). We performed a sensitivity analysis because considerable heterogeneity was noted (I<sup>2</sup> = 92%). After the smallest study had been excluded (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>), results still showed significant differences with lower heterogeneity (RR 9.34, 95% CI 5.43 to 16.05, I<sup>2</sup> = 53%; not shown). Subgroup analyses showed that gynaecomastia occurred more often with bicalutamide 50 mg daily (RR 14.07, 95% CI 3.74 to 52.85), flutamide 250 mg three times daily (RR 3.70, 95% CI 1.33 to 10.33), bicalutamide 450 mg daily (RR 27.88, 95% CI 7.02 to 110.79) and bicalutamide 600 mg daily (RR 20.36, 95% CI 4.97 to 83.40). However, no significant difference was found between bicalutamide 150 mg daily and castration. We performed a sensitivity analysis because heterogeneity (I<sup>2</sup> = 97%) was present for this comparison. After the smallest study had been excluded (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>), a significant increase in gynaecomastia with reduced heterogeneity was found with bicalutamide 150 mg daily (RR 8.79, 95% CI 3.88 to 18.94, I<sup>2</sup> = 67%; not shown). </p> <p>The occurrence of asthenia was significantly increased when non‐steroidal antiandrogens were used compared with castration (RR 1.77, 95% CI 1.36 to 2.31, 2073 participants; <a href="./references#CD009266-fig-0026" title="">Analysis 1.23</a>). Subgroup analyses showed higher incidences of asthenia with bicalutamide 50 mg, 150 mg and 450 mg daily (<a href="./references#CD009266-fig-0026" title="">Analysis 1.23</a>). No significant difference was found between bicalutamide 600 mg daily and castration (RR 2.45, 95% CI 0.95 to 6.31, 132 participants; <a href="./references#CD009266-fig-0026" title="">Analysis 1.23</a>). </p> <p>No differences in the risk of suffering arthralgia were found between non‐steroidal antiandrogens and castration in overall analysis and subgroup analysis for bicalutamide 600 mg daily (<a href="./references#CD009266-fig-0049" title="">Analysis 1.46</a>). However, the occurrence of arthralgia was significantly increased with the non‐steroidal antiandrogen bicalutamide at a dose of 450 mg daily compared with castration (RR 1.96, 95% CI 1.01 to 3.80, 182 participants; <a href="./references#CD009266-fig-0049" title="">Analysis 1.46</a>). </p> <p>One small study (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>) of participants receiving bicalutamide 150 mg daily showed that non‐steroidal antiandrogens might preserve sexual interest compared with castration (RR 0.50, 95% CI 0.30 to 0.83, 51 participants; <a href="./references#CD009266-fig-0025" title="">Analysis 1.22</a>). </p> <p>Risk of hot flashes (RR 0.23, 95% CI 0.19 to 0.27, 2774 participants; <a href="./references#CD009266-fig-0028" title="">Analysis 1.25</a>), haemorrhage (RR 0.07, 95% CI 0.01 to 0.54, 546 participants; <a href="./references#CD009266-fig-0041" title="">Analysis 1.38</a>), nocturia (RR 0.38, 95% CI 0.20 to 0.69, 480 participants; <a href="./references#CD009266-fig-0043" title="">Analysis 1.40</a>), urinary frequency (RR 0.22, 95% CI 0.11 to 0.47, 480 participants; <a href="./references#CD009266-fig-0044" title="">Analysis 1.41</a>) and occurrence of fatigue (RR 0.52, 95% CI 0.31 to 0.88, 51 participants; <a href="./references#CD009266-fig-0052" title="">Analysis 1.49</a>) was decreased with non‐steroidal antiandrogens compared with castration. These significant differences were also evident for all subgroup analyses regarding the different doses of non‐steroidal antiandrogens. </p> <p>The overall risk to suffer night sweats was decreased with non‐steroidal antiandrogens compared with castration (RR 0.29, 95% CI 0.17 to 0.49, 1571 participants; <a href="./references#CD009266-fig-0029" title="">Analysis 1.26</a>). However, although a significant difference was noted in the subgroup of participants treated with bicalutamide 150 mg daily (RR 0.26, 95% CI 0.14 to 0.49, 1268 participants), this finding was not evident for participants treated with bicalutamide 50 mg daily (RR 0.36, 95% CI 0.12 to 1.09, 303 participants). </p> <p>Infection occurred less frequently with bicalutamide at 50 mg daily but showed no significant difference for overall analysis or bicalutamide at 150 mg daily when compared with castration (<a href="./references#CD009266-fig-0035" title="">Analysis 1.32</a>). </p> <p>The occurrence of peripheral oedema was significantly decreased for bicalutamide at 50 mg daily (RR 0.42, 95% CI 0.21 to 0.82, 480 participants); however, we found no statistically significant difference for bicalutamide at 150 mg daily compared with castration and in overall analysis (<a href="./references#CD009266-fig-0046" title="">Analysis 1.43</a>). </p> <p>We found an increased occurrence of constipation (<a href="./references#CD009266-fig-0021" title="">Analysis 1.18</a>) and a decreased risk of anaemia (<a href="./references#CD009266-fig-0030" title="">Analysis 1.27</a>) with higher doses of non‐steroidal antiandrogens compared with castration. </p> <p>No significant difference between non‐steroidal antiandrogens and castration was noted for occurrence of haematuria (<a href="./references#CD009266-fig-0042" title="">Analysis 1.39</a>). However, results of the meta‐analysis including two studies (<a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>) show considerable heterogeneity (I<sup>2</sup> = 97%). Subgroup analyses showed a significantly decreased risk with bicalutamide 50 mg daily but an increased risk with bicalutamide 150 mg daily to suffer haematuria when compared with castration (bicalutamide 50 mg daily: RR 0.41, 95% CI 0.26 to 0.67, 480 participants; bicalutamide 150 mg daily: RR 3.49, 95% CI 2.01 to 6.05, 474 participants; <a href="./references#CD009266-fig-0042" title="">Analysis 1.39</a>). </p> <p>Conflicting results were found for the occurrence of vomiting because events in both groups were very rare (<a href="./references#CD009266-fig-0023" title="">Analysis 1.20</a>). </p> <p>We identified no statistically significant differences for the following adverse events when we compared non‐steroidal antiandrogens with castration: pelvic pain (<a href="./references#CD009266-fig-0014" title="">Analysis 1.11</a>), bone pain (<a href="./references#CD009266-fig-0015" title="">Analysis 1.12</a>), back pain (<a href="./references#CD009266-fig-0016" title="">Analysis 1.13</a>), headache (<a href="./references#CD009266-fig-0017" title="">Analysis 1.14</a>), abdominal pain (<a href="./references#CD009266-fig-0018" title="">Analysis 1.15</a>), general pain (<a href="./references#CD009266-fig-0019" title="">Analysis 1.16</a>), gastralgia (<a href="./references#CD009266-fig-0050" title="">Analysis 1.47</a>), diarrhoea (<a href="./references#CD009266-fig-0022" title="">Analysis 1.19</a>), hypertension (<a href="./references#CD009266-fig-0024" title="">Analysis 1.21</a>), nausea (<a href="./references#CD009266-fig-0051" title="">Analysis 1.48</a>), insomnia (<a href="./references#CD009266-fig-0027" title="">Analysis 1.24</a>), hepatic enzyme increase (<a href="./references#CD009266-fig-0031" title="">Analysis 1.28</a>), rash (<a href="./references#CD009266-fig-0032" title="">Analysis 1.29</a>), pruritus (<a href="./references#CD009266-fig-0033" title="">Analysis 1.30</a>), dyspnoea (<a href="./references#CD009266-fig-0034" title="">Analysis 1.31</a>), pharyngitis (<a href="./references#CD009266-fig-0036" title="">Analysis 1.33</a>), arthritis (<a href="./references#CD009266-fig-0037" title="">Analysis 1.34</a>), sinusitis (<a href="./references#CD009266-fig-0038" title="">Analysis 1.35</a>), urinary tract infection (<a href="./references#CD009266-fig-0039" title="">Analysis 1.36</a>), dizziness (<a href="./references#CD009266-fig-0040" title="">Analysis 1.37</a>), urinary retention (<a href="./references#CD009266-fig-0045" title="">Analysis 1.42</a>), anorexia (<a href="./references#CD009266-fig-0047" title="">Analysis 1.44</a>), loss of sexual function (<a href="./references#CD009266-fig-0048" title="">Analysis 1.45</a>), dry skin (<a href="./references#CD009266-fig-0053" title="">Analysis 1.50</a>), aggravation reaction (<a href="./references#CD009266-fig-0054" title="">Analysis 1.51</a>) and serious adverse events (<a href="./references#CD009266-fig-0055" title="">Analysis 1.52</a>). </p> <p>No study reported data on the predefined outcomes of cardiovascular events, gastrointestinal disorders and lethargy. </p> <p>The quality of evidence for breast pain, gynaecomastia and hot flashes was moderate (<a href="./full#CD009266-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009266-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009266-sec-0105"></div> <section id="CD009266-sec-0106"> <h3 class="title" id="CD009266-sec-0106">Summary of main results</h3> <p>Eleven studies were included. The quality of the evidence for overall survival, clinical progression, treatment failure, breast pain, gynaecomastia and hot flashes was moderate (<a href="./full#CD009266-tbl-0001">summary of findings Table for the main comparison</a>). Non‐steroidal antiandrogens significantly decreased overall survival and increased clinical progression as well as treatment failure. Subgroup analyses showed that non‐steroidal antiandrogens, compared with castration, were consistently less favourable for overall survival, clinical progression and treatment failure in men with metastatic disease. Additionally, less favourable effects were seen with the non‐steroidal antiandrogen bicalutamide 50 mg daily for overall survival, clinical progression with imputed event numbers at 70 weeks and treatment failure with imputed event numbers at 70 weeks, as well as for the non‐steroidal antiandrogen bicalutamide 150 mg daily for clinical progression and treatment failure at one year, 70 weeks and two years, when compared with castration. Non‐steroidal antiandrogens also increased the risk for treatment discontinuation due to adverse events and increased the risk of breast pain, gynaecomastia and asthenia. The risk of other adverse events, such as hot flashes, fatigue, loss of sexual interest, haemorrhage, nocturia and urinary frequency, was significantly increased with castration. Effects of non‐steroidal antiandrogens on cancer‐specific survival and biochemical progression remained unclear. </p> </section> <section id="CD009266-sec-0107"> <h3 class="title" id="CD009266-sec-0107">Overall completeness and applicability of evidence</h3> <p>The included studies examined clinically important populations that were representative of patients seen in routine clinical practice. These participants and assessed interventions directly conformed to the review question. However, several points must be considered regarding the applicability of evidence. </p> <p>The included studies provided data on our predefined outcomes. However, four studies (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>; <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>) did not address the review question directly and instead assessed primary outcomes that were not relevant to the review question, such as bone mineral density (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>), arterial stiffness (<a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>), metabolic changes (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>) and markers of neuroendocrine differentiation (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>). However, these studies also reported data on adverse events and/or progression and therefore were included in the review. </p> <p>Only three studies were evaluated for biochemical progression. However, this outcome was defined by the authors in two of the three studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>) as clinical progression. In accordance with our predetermined definition, we classified these reported outcomes as biochemical progression because a PSA measurement was used for the definition of this outcome. The definition of biochemical progression varied among the included studies. The results of this outcome assessment should be interpreted carefully. </p> <p>The two largest included studies (<a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>) assessed participants with non‐metastatic and metastatic prostate cancer. PSA values were measured for participants with non‐metastatic disease only. For participants in the non‐steroidal antiandrogen group, these values ranged between 0.1 and 7691 ng/mL (median 69.2 ng/mL, mean 173.2 ng/mL). These rather high PSA values might no longer represent populations with non‐metastatic disease and might lead to bias in the evaluations. </p> <p>We included seven studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>) that assessed men treated with surgical castration. This therapy is suggested as a potential alternative to medical castration (<a href="./references#CD009266-bbs2-0089" title="AbrahamssonPA , AndersonJ , Boccon‐GibodL , SchulmanC , StuderUE , WirthM . Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer. European Urology2005;48(6):900‐5. ">Abrahamsson 2005</a>; <a href="./references#CD009266-bbs2-0092" title="LoblawDA , MendelsonDS , TalcottJA , VirgoKS , SomerfieldMR , Ben‐JosefE , et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen‐sensitive metastatic, recurrent, or progressive prostate cancer. Journal of Clinical Oncology2004;22(14):2927‐41. ">ASCO 2004</a>; <a href="./references#CD009266-bbs2-0093" title="LoblawDA , VirgoKS , NamR , SomerfieldMR , Ben‐JosefE , MendelsonDS , et al. Initial hormonal management of androgen‐sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology2007;25(12):1596‐605. ">ASCO 2007</a>; <a href="./references#CD009266-bbs2-0134" title="SeidenfeldJ , SamsonDJ , AronsonN , AlbertsonPC , BayoumiAM , BennettC , et al. Relative effectiveness and cost‐effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/technology Assessment (Summary)1999; Vol. 4:1‐246. ">Seidenfeld 1999</a>; <a href="./references#CD009266-bbs2-0135" title="SeidenfeldJ , SamsonDJ , HasselbladV , AronsonN , AlbertsenPC , BennettCL , et al. Single‐therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta‐analysis. Annals of Internal Medicine2000;132(7):566‐77. ">Seidenfeld 2000</a>). However, surgical castration could lead to potential psychological strain, and the resulting adverse events are only partially treatable. Nyman et al suggested that when patients can choose between different androgen suppression therapy options (non‐steroidal antiandrogens and medical or surgical castration) and receive comprehensive information about the treatment, nearly all patients are satisfied with their choice after three months of treatment (<a href="./references#CD009266-bbs2-0063" title="NymanCR , AndersenJT , LoddingP , SandinT , VarenhorstE . The patient's choice of androgen‐deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin‐releasing hormone analogue or orchidectomy. BJU International2005;96(7):1014‐8. ">Nyman 2005</a>). However, it should be mentioned that the clinical heterogeneity of these treatments might lead to bias in our results regarding treatment discontinuation due to adverse events because reversal of surgical castration is not possible. </p> </section> <section id="CD009266-sec-0108"> <h3 class="title" id="CD009266-sec-0108">Quality of the evidence</h3> <p>Most of the included studies reported insufficient information on sequence generation and allocation concealment. </p> <p>No study performed blinding of participants and personnel because different therapy options were included (surgical castration, oral medication and injection therapy). Opinions vary as to whether lack of blinding has a relevant impact on outcomes such as overall survival, cancer‐specific mortality and biochemical progression. It might be conceivable that these outcomes are influenced by lack of blinding. Therefore we judged that risk of bias for most of the included studies is unclear regarding overall survival, cancer‐specific mortality and biochemical progression. Outcomes such as clinical progression, treatment failure, treatment discontinuation due to adverse events and adverse events could be influenced by lack of blinding, presenting a high risk of bias in most of the included studies. Therefore the effects of intervention may have been overestimated (<a href="./references#CD009266-bbs2-0091" title="Als‐NielsenB , GluudLL , GluudC . Methodological quality and treatment effects in randomized trials: a review of six empirical studies. Meeting abstract of the 12th Cochrane Colloquium, Ottawa (Canada). 2004. www.cochrane.org/events/colloquia. ">Als‐Nielsen 2004</a>; <a href="./references#CD009266-bbs2-0127" title="PildalJ , HróbjartssonA , JørgensenKJ , HildenJ , AltmanDG , GøtzschePC . Impact of allocation concealment on conclusions drawn from meta‐analyses of randomized trials. International Journal of Epidemiology2007;36(4):847‐57. ">Pildal 2007</a>; <a href="./references#CD009266-bbs2-0147" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336(7644):601‐5. ">Wood 2008</a>). </p> <p>In all studies, no blinding of outcome assessment was performed or blinding was not reported or underlying methodology remained unclear. However, this type of blinding would have been feasible and could have been expected in all studies. We suggest that it is not likely that outcome assessments for overall survival, cancer‐specific mortality and biochemical progression are influenced by lack of blinding. For outcomes such as clinical progression, treatment failure, treatment discontinuation due to adverse events and adverse events, this lack of blinding might, however, introduce detection bias due to potentially overestimated intervention effects (<a href="./references#CD009266-bbs2-0127" title="PildalJ , HróbjartssonA , JørgensenKJ , HildenJ , AltmanDG , GøtzschePC . Impact of allocation concealment on conclusions drawn from meta‐analyses of randomized trials. International Journal of Epidemiology2007;36(4):847‐57. ">Pildal 2007</a>). </p> <p>The results of five studies (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>) were based on data for which risk for incomplete outcomes was high. A risk of bias is present because per‐protocol analyses may lead to overestimated effects (<a href="./references#CD009266-bbs2-0090" title="AklEA ,  BrielM ,  YouJJ ,  SunX ,  JohnstonBC ,  BusseJW ,  etal . Potential impact on estimated treatment effects of information lost to follow‐up in randomised controlled trials (LOST‐IT): systematic review. BMJ (Clinical Research Ed.)2012;18(344):e2809. ">Akl 2012</a>; <a href="./references#CD009266-bbs2-0122" title="MeerpohlJJ , WolffRF , NiemeyerCM , AntesG , vonElmE . Editorial policies of pediatric journals: survey of instructions for authors. Archives of Pediatrics &amp; Adolescent Medicine2010;164(3):268‐72. ">Meerpohl 2010</a>; <a href="./references#CD009266-bbs2-0128" title="PortaN , BonetC , CoboE . Discordance between reported intention‐to‐treat and per protocol analyses. Journal of Clinical Epidemiology2007;60(7):663‐9. ">Porta 2007</a>; <a href="./references#CD009266-bbs2-0132" title="SchulzKF , GrimesDA , AltmanDG , HayesRJ . Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology. BMJ (Clinical Research Ed.)1996;312(7033):742‐4. ">Schulz 1996</a>; <a href="./references#CD009266-bbs2-0140" title="TierneyJF , StewartLA . Investigating patient exclusion bias in meta‐analysis. International Journal of Epidemiology2005;34(1):79‐87. ">Tierney 2005</a>; <a href="./references#CD009266-bbs2-0146" title="WoodAM , WhiteIR , ThompsonSG . A review of published randomized controlled trials in major medical journals. Clinical Trials (London, England)2004;1(4):368‐76. ">Wood 2004</a>). We performed sensitivity analyses based on best‐/worst‐case scenarios for outcomes such as treatment failure (<a href="./references#CD009266-fig-0012" title="">Analysis 1.9</a>), biochemical progression (<a href="./references#CD009266-fig-0010" title="">Analysis 1.7</a>) and clinical progression (<a href="./references#CD009266-fig-0008" title="">Analysis 1.5</a>) with imputations of missing data to minimise this bias because ITT analyses are regarded as the preferred way to estimate the effects of interventions in randomised controlled trials (<a href="./references#CD009266-bbs2-0123" title="NewellDJ . Intention‐to‐treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology1992;21(5):837‐41. ">Newell 1992</a>). </p> <p>Possible conflicts of interest should be considered for all of the included studies because the trial authors reported a possible conflict of interest or provided no disclosure statement. Conflicts of interest are common in the field of urology (<a href="./references#CD009266-bbs2-0112" title="HampsonLA , MontieJE . Conflict of interest in urology. Journal of Urology2012;187(6):1971‐7. ">Hampson 2012</a>; <a href="./references#CD009266-bbs2-0129" title="RammO , BrubakerL . Conflicts‐of‐interest disclosures at the 2010 AUGS Scientific Meeting. Female Pelvic Medicine &amp; Reconstructive Surgery2012;18(2):79‐81. ">Ramm 2012</a>). Conflicts of interest may introduce a risk of bias because studies funded by industry have been shown to be more likely to report positive results than studies with other funding sources (<a href="./references#CD009266-bbs2-0111" title="Gøtzsche PC , HróbjartssonA , JohansenHK , HaahrMT , AltmanDG , ChanAW . Constraints on publication rights in industry‐initiated clinical trials. JAMA2006;295(14):1645‐6. ">Gøtzsche 2006</a>; <a href="./references#CD009266-bbs2-0125" title="OkikeK , KocherMS , MehlmanCT , BhandariM . Conflict of interest in orthopaedic research. An association between findings and funding in scientific presentations. Journal of Bone and Joint Surgery. American Volume2007;89(3):608‐13. ">Okike 2007</a>; <a href="./references#CD009266-bbs2-0136" title="ShahRV , AlbertTJ , Bruegel‐SanchezV , VaccaroAR , HilibrandAS , GrauerJN . Industry support and correlation to study outcome for papers published in Spine. Spine2005;30(9):1099‐104. ">Shah 2005</a>). However, the risk of bias remains unclear because lack of a disclosure statement in itself is not an indicator of bias. Peer reviewers and journal editors may require conflict of interest disclosures at any step of the peer review process without providing a summary statement on the issue (<a href="./references#CD009266-bbs2-0122" title="MeerpohlJJ , WolffRF , NiemeyerCM , AntesG , vonElmE . Editorial policies of pediatric journals: survey of instructions for authors. Archives of Pediatrics &amp; Adolescent Medicine2010;164(3):268‐72. ">Meerpohl 2010</a>). </p> <p>Non‐steroidal antiandrogens were assessed using subgroup analyses regarding disease stage. The two largest included studies (<a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>) recruited participants with metastatic or non‐metastatic prostate cancer. However, participants with metastatic disease withdrew from the study early (after 100 weeks) and were excluded from further evaluations. We did not examine the protocols for these studies; it is therefore unclear whether the subgroup analyses were predefined. Post hoc subgroup analyses are common and might introduce a risk that differences in effect sizes across subgroups could produce statistically significant differences (<a href="./references#CD009266-bbs2-0138" title="SunX , BrielM , BusseJW , AklEA , YouJJ , MejzaF , et al. Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials. Trials2009;10:101. ">Sun 2009</a>; <a href="./references#CD009266-bbs2-0139" title="SunX , BrielM , BusseJW , YouJJ , AklEA , MejzaF , et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ (Clinical Research Ed.)2012;344:e1553. ">Sun 2012</a>; <a href="./references#CD009266-bbs2-0142" title="WangSS , OuYC , ChengCL , DahmP . Evidence‐based urology in practice: when to believe a subgroup analysis?. BJU International2010;105(2):162‐4. ">Wang 2010</a>). The influence of subgroup effects might be low (<a href="./references#CD009266-bbs2-0139" title="SunX , BrielM , BusseJW , YouJJ , AklEA , MejzaF , et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ (Clinical Research Ed.)2012;344:e1553. ">Sun 2012</a>; <a href="./references#CD009266-bbs2-0142" title="WangSS , OuYC , ChengCL , DahmP . Evidence‐based urology in practice: when to believe a subgroup analysis?. BJU International2010;105(2):162‐4. ">Wang 2010</a>) and should be interpreted carefully. </p> <p>Overall, we identified several methodological limitations during our assessment of risk of bias, leading to downgrading of the quality of evidence for study limitations (section <a href="./references#CD009266-sec-0135" title="">Characteristics of included studies</a>; <a href="#CD009266-fig-0003">Figure 3</a>). No indication of publication bias was found by funnel plot asymmetry analysis for our primary outcome, and we believe that risk of publication bias might be low (<a href="#CD009266-sec-0065">Risk of bias in included studies</a>; <a href="#CD009266-fig-0002">Figure 2</a>). Heterogeneity was noted for overall survival, clinical progression, treatment failure and gynaecomastia. However, this heterogeneity might be explained by subgroup or sensitivity analyses (see <a href="#CD009266-sec-0083">Effects of interventions</a>); we believe that it should not be required that the quality of the evidence should be downgraded for inconsistency. Additionally, we believe that it might not be necessary to downgrade the quality of the evidence because of imprecision. The quality of the body of evidence for outcomes such as overall survival, clinical progression, treatment failure, breast pain, gynaecomastia and hot flashes was therefore rated as moderate (<a href="./full#CD009266-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD009266-sec-0109"> <h3 class="title" id="CD009266-sec-0109">Potential biases in the review process</h3> <section id="CD009266-sec-0110"> <h4 class="title">Limitations of the review at the study or outcome level</h4> <p>All studies were published in peer‐reviewed publications. However, results might be hampered by several limitations. As discussed above, included participants might no longer represent the contemporary population (see <a href="#CD009266-sec-0107">Overall completeness and applicability of evidence</a>). Additionally, only two included studies (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>) measured PSA as a marker for clinical or biochemical progression. Nowadays, PSA plays an important role in the follow‐up of patients with prostate cancer and in early detection of disease progression. This certainly has an effect on clinical and biochemical progression and might be important for outcomes such as overall and cancer‐specific mortality. </p> </section> <section id="CD009266-sec-0111"> <h4 class="title">Limitations of the review at the review level</h4> <p>We followed the recommendations outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to minimise potential biases (<a href="./references#CD009266-bbs2-0116" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011a</a>). We performed an extensive literature search and contacted selected experts in the field, as well as manufacturers of non‐steroidal androgen suppression drugs, to request information on unpublished studies. Therefore it is not likely that relevant studies were overlooked. Two review authors independently assessed the information given in the reports of included studies and contacted the investigators of the identified studies to request supplemental data. This review therefore assessed the best evidence available from published randomised controlled trials. Unfortunately, even after contacting the primary investigators, we received no additional data. </p> <section id="CD009266-sec-0112"> <h5 class="title">Limitations of the review related to detection of serious and/or rare adverse events</h5> <p>We considered only randomised controlled trials for inclusion in this review. However, for evaluation of serious and/or rare adverse events, it is also necessary to consider non‐randomised studies such as controlled clinical trials, cohort studies and case‐control studies. Observational studies often utilise large databases and likely or possibly show greater external validity when compared with data from randomised controlled trials (<a href="./references#CD009266-bbs2-0106" title="GartlehnerG . Assessment of adverse effects and applicability ‐ two areas not (yet) covered adequately in Cochrane reports. Zeitschrift fur Evidenz, Fortbildung und Qualitat Im Gesundheitswesen2008;102(8):497‐502. ">Gartlehner 2008</a>). Additionally, data on adverse events from randomised controlled trials could underestimate rare but serious adverse events as the result of small sample size and might be susceptible to bias due to the inclusion of highly selected participants (<a href="./references#CD009266-bbs2-0097" title="ChouR , AronsonN , AtkinsD , IsmailaAS , SantaguidaP , SmithDH , et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health‐care program. Journal of Clinical Epidemiology2010;63(5):502‐12. ">Chou 2010</a>). </p> </section> </section> </section> <section id="CD009266-sec-0113"> <h3 class="title" id="CD009266-sec-0113">Agreements and disagreements with other studies or reviews</h3> <p>We identified that overall survival was significantly decreased with non‐steroidal antiandrogens when compared with castration. This is consistent with the findings of other studies. A systematic review published in 2000 by Seidenfeld et al already suggested that overall survival might be lower when non‐steroidal antiandrogens are used (<a href="./references#CD009266-bbs2-0134" title="SeidenfeldJ , SamsonDJ , AronsonN , AlbertsonPC , BayoumiAM , BennettC , et al. Relative effectiveness and cost‐effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/technology Assessment (Summary)1999; Vol. 4:1‐246. ">Seidenfeld 1999</a>; <a href="./references#CD009266-bbs2-0135" title="SeidenfeldJ , SamsonDJ , HasselbladV , AronsonN , AlbertsenPC , BennettCL , et al. Single‐therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta‐analysis. Annals of Internal Medicine2000;132(7):566‐77. ">Seidenfeld 2000</a>). However, no update was performed of the review published by Seidenfeld et al, and no other systematic review evaluating overall or cancer‐specific survival was published comparing non‐steroidal antiandrogens with medical or surgical castration. A narrative review suggested that non‐steroidal antiandrogen monotherapy is an established treatment option in men with prostate cancer, but that an unexplained trend towards increased mortality should prohibit their uncritical use (<a href="./references#CD009266-bbs2-0144" title="WirthMP , HakenbergOW , FroehnerM . Antiandrogens in the treatment of prostate cancer. European Urology2007;51(2):306‐14. ">Wirth 2007</a>). The Early Prostate Cancer program investigated the effect of bicalutamide 150 mg daily compared with placebo. It showed that bicalutamide might delay clinical progression, but that for overall survival, it provided an advantage only when combined with external beam radiotherapy for locally advanced prostate cancer (<a href="./references#CD009266-bbs2-0030" title="FourcadeRO , RichaudP , BruneD , ColombelP , SarramonJP , FournierG , et al. Effect of bicalutamide 150 mg, after 3 years of median follow‐up, in non‐metastatic prostatic cancer [Effet du bicalutamide 150 mg, à trois ans de suivi médian, dans le cancer de la prostate non métastatique]. Progres en Urologie2003;13(3):430‐9. FourcadeRO , RichaudP , ColobyP , MalavaudB , Group des investigateuers français du programme EPC. Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program [Le bicalutamide 150 mg dans le traitement du cancer de la prostate localement avancé : des résultats à la pratique : Place du bicalutamide 150 mg dans le traitement du cancer de la prostate : hème analyse du programme EPC (Early Prostate Cancer)]. Progres en Urologie2007;17(4 Suppl 1):891‐910. IversenP , JohanssonJ‐E , LoddingP , LukkarinenO , LundmoPI , KlarskovP , et al. Efficacy and tolerability of bicalutamide in early non‐metastatic prostate cancer: Latest findings from the Scandinavian Prostatic Cancer Group Study No 6 (SPCG‐6) of the early prostate cancer programme. Meeting abstract of the 21st annual European Association of Urology Congress. 2006. www.uroweb.org/index.php?id=108&amp;AID=9715. IversenP , JohanssonJE , LoddingP , KylmalaT , LundmoP , KlarskovP , et al. Bicalutamide 150 mg in addition to standard care for patients with early non‐metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group‐6 Study after a median follow‐up period of 7.1 years. Scandinavian Journal of Urology and Nephrology2006;40(6):441‐52. IversenP , JohanssonJE , LoddingP , LukkarinenO , LundmoP , KlarskovP , et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3 year median followup from the Scandinavian Prostate Cancer Group Study Number 6. Journal of Urology2004;172(5 Pt 1):1871‐6. IversenP , McLeodD , SeeW , WirthM , MorrisT , MorrisC , et al. Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non‐metastatic prostate cancer: updated analysis at a median 5.4 years’ follow‐up. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=758. IversenP , McLeodDG , SeeWA , MorrisT , ArmstrongJ , WirthMP . Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years. BJU International2010;105(8):1074‐81. IversenP , RoderMA . The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Review of Anticancer Therapy2008;8(3):361‐9. IversenP , TammelaTLJ , VaageS , LukkarinenO , LoddingP , Bull‐NjaaT , et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non‐metastatic prostate cancer ‐ First report from the Scandinavian Prostatic Cancer Group Study No. 6. European Urology2002;42(3):204‐11. IversenP , WirthMP , SeeWAII , McLeodDG , MorrisT , ArmstrongJ , et al. The influence of nodal status on progression outcomes in patients with prostate cancer: data from the Early Prostate Cancer program at 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4628. IversenP , WirthMP , SeeWA , McLeodDG , KlimbergI , GleasonD , et al. Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology2004;63(5):928‐33. McLeodD , IversenP , SeeW , WirthM , CarrollK , MorrisC , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy significantly improves progression‐free survival in early non‐metastatic prostate cancer: results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow‐up. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=752. McLeodDG , IversenP , SeeWA , MorrisT , ArmstrongJ , WirthMP . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU International2006;97(2):247‐54. McLeodDG , SeeWA , KlimbergI , GleasonD , ChodakG , MontieJ , et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7‐year median followup. Journal of Urology2006;176(1):75‐80. SeeW , IversenP , WirthM , McLeodD , GarsideL , MorrisT . Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology2003;44(5):512‐8. SeeWA , McLeodD , IversenP , WirthM . The bicalutamide Early Prostate Cancer Program: demography. Urologic Oncology2001;6(2):43‐7. SeeWA , McLeodDG , IversenP , WirthMP , ArmstrongJ , NavaniS . Effect of bicalutamide 150 mg on PSA progression in M0 prostate cancer: results from Early Prostate Cancer program. Journal of Clinical Oncology2006;24(18 Suppl):4624. SeeWA , TyrrellCJ . The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. Journal of Cancer Research and Clinical Oncology2006;132 Suppl 1:S7‐16. SeeWA , WirthMP , McLeodDG , IversenP , KlimbergI , GleasonD , et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. Journal of Urology2002;168(2):429‐35. TyrrellC . Immediate treatment with bicalutamide, 150 mg/d, following radiotherapy in localized or locally advanced prostate cancer. Reviews in Urology2004;6 Suppl 2:S29‐36. TyrrellCJ , PayneH , SeeWA , McLeodDG , WirthMP , IversenP , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiotherapy and Oncology2005;76(1):4‐10. WirthM , HakenbergO , FroehnerM . Adjuvant hormonal treatment ‐ the Bicalutamide Early Prostate Cancer Program. Frontiers of Radiation Therapy and Oncology2008;41:39‐48. WirthM , IversenP , McLeodD , SeeW , MorrisC , MorrisT , et al. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression‐free survival in patients with early non‐metastatic prostate cancer: analysis at a median follow‐up of 5.4 years. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=560. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceD , et al. Adjuvant therapy with bicalutamide 150 mg versus standard care alone: third analysis results from Trial 24 of the Early Prostate Cancer programme. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=9672. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double‐blind phase III study (median follow‐up 5.1 y) in the early prostate cancer programme. Prostate Cancer and Prostatic Diseases2005;8(2):194‐200. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide (Casodex) 150 mg plus standard care in early non‐metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow‐up. Prostate Cancer and Prostatic Diseases2007;10(1):87‐93. WirthM , TyrrellC , WallaceM , DelaereKP , Sánchez‐ChapadoM , RamonJ , et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology2001;58(2):146‐51. WirthMP , FroehnerM . Adjuvant hormonal treatment for prostate cancer: the Bicalutamide Early Prostate Cancer Program. Oncology2003;65 Suppl 1:1‐4. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , ArmstrongJ . Delaying metastatic disease progression in locally advanced disease ‐ results from the Early Prostate Cancer program at a median follow‐up of 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4629. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , CarrollK . Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. Journal of Urology2004;172(5 Pt 1):1865‐70. ">EPC program</a>; <a href="./references#CD009266-bbs2-0145" title="WirthMP , HakenbergOW , FroehnerM . Adjuvant hormonal treatment ‐ the bicalutamide early prostate cancer program. Frontiers of Radiation Therapy and Oncology2008;41:39‐48. ">Wirth 2008</a>). </p> <p>Non‐steroidal antiandrogens are thought to provide advantages such as oral application and the potential preservation of libido, potency and muscle mass or bone mineral density when compared with castration (<a href="./references#CD009266-bbs2-0101" title="HeidenreichA , BastianPJ , BellmuntJ , BollaM , JoniauS , MasonMD , et al. Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013). ">EAU 2013</a>; <a href="./references#CD009266-bbs2-0098" title="DaniellHW . Osteoporosis after orchiectomy for prostate cancer. Journal of Urology1997;157(2):439‐44. ">Daniell 1997</a>; <a href="./references#CD009266-bbs2-0067" title="PreziosoD , BartolettiR , CecchiM , CicaleseV , CunicoSC , DamianoR , et al. Quality of life evaluation by the EORTC QLQ‐C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study. Archivio Italiano di Urologia, Andrologia2007;79(3):99‐103. ">Prezioso 2007</a>; <a href="./references#CD009266-bbs2-0074" title="SciarraA , CardiA , DiSilverioF . Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urologia Internationalis2004;72(2):91‐8. ">Sciarra 2004b</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0137" title="SmithMR . Osteoporosis during androgen deprivation therapy for prostate cancer. Urology2002;60(3 Suppl 1):79‐85. ">Smith 2002</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0084" title="WadhwaV , WestonR , ParrNJ . Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health‐related quality of life benefits for osteoporotic men with prostate cancer. BJU International2011;107(12):1923‐9. ">Wadhwa 2011</a>). However, adverse events should be considered. This review suggests that the occurrence of adverse events such as breast pain, gynaecomastia and asthenia is increased with non‐steroidal antiandrogens. Breast events were the most common adverse events in recent reports of treatment with non‐steroidal antiandrogens (<a href="./references#CD009266-bbs2-0095" title="BoccardoF , RubagottiA , BarichelloM , BattagliaM , CarmignaniG , ComeriG , et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. Journal of Clinical Oncology1999;17(7):2027‐38. ">Boccardo 1999</a>; <a href="./references#CD009266-bbs2-0020" title="BoccardoF , BarichelloM , BattagliaM , CarmignaniG , ComeriG , FerrarisV , et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. European Urology2002;42(5):481‐90. BoccardoF , RubagottiA , BorichelloM , BattagliaM , CarmignaniG , ComeriG , et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. Journal of Clinical Oncology1999;17(7):2027‐38. ">Boccardo 2002</a>; <a href="./references#CD009266-bbs2-0030" title="FourcadeRO , RichaudP , BruneD , ColombelP , SarramonJP , FournierG , et al. Effect of bicalutamide 150 mg, after 3 years of median follow‐up, in non‐metastatic prostatic cancer [Effet du bicalutamide 150 mg, à trois ans de suivi médian, dans le cancer de la prostate non métastatique]. Progres en Urologie2003;13(3):430‐9. FourcadeRO , RichaudP , ColobyP , MalavaudB , Group des investigateuers français du programme EPC. Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program [Le bicalutamide 150 mg dans le traitement du cancer de la prostate localement avancé : des résultats à la pratique : Place du bicalutamide 150 mg dans le traitement du cancer de la prostate : hème analyse du programme EPC (Early Prostate Cancer)]. Progres en Urologie2007;17(4 Suppl 1):891‐910. IversenP , JohanssonJ‐E , LoddingP , LukkarinenO , LundmoPI , KlarskovP , et al. Efficacy and tolerability of bicalutamide in early non‐metastatic prostate cancer: Latest findings from the Scandinavian Prostatic Cancer Group Study No 6 (SPCG‐6) of the early prostate cancer programme. Meeting abstract of the 21st annual European Association of Urology Congress. 2006. www.uroweb.org/index.php?id=108&amp;AID=9715. IversenP , JohanssonJE , LoddingP , KylmalaT , LundmoP , KlarskovP , et al. Bicalutamide 150 mg in addition to standard care for patients with early non‐metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group‐6 Study after a median follow‐up period of 7.1 years. Scandinavian Journal of Urology and Nephrology2006;40(6):441‐52. IversenP , JohanssonJE , LoddingP , LukkarinenO , LundmoP , KlarskovP , et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3 year median followup from the Scandinavian Prostate Cancer Group Study Number 6. Journal of Urology2004;172(5 Pt 1):1871‐6. IversenP , McLeodD , SeeW , WirthM , MorrisT , MorrisC , et al. Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non‐metastatic prostate cancer: updated analysis at a median 5.4 years’ follow‐up. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=758. IversenP , McLeodDG , SeeWA , MorrisT , ArmstrongJ , WirthMP . Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years. BJU International2010;105(8):1074‐81. IversenP , RoderMA . The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Review of Anticancer Therapy2008;8(3):361‐9. IversenP , TammelaTLJ , VaageS , LukkarinenO , LoddingP , Bull‐NjaaT , et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non‐metastatic prostate cancer ‐ First report from the Scandinavian Prostatic Cancer Group Study No. 6. European Urology2002;42(3):204‐11. IversenP , WirthMP , SeeWAII , McLeodDG , MorrisT , ArmstrongJ , et al. The influence of nodal status on progression outcomes in patients with prostate cancer: data from the Early Prostate Cancer program at 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4628. IversenP , WirthMP , SeeWA , McLeodDG , KlimbergI , GleasonD , et al. Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology2004;63(5):928‐33. McLeodD , IversenP , SeeW , WirthM , CarrollK , MorrisC , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy significantly improves progression‐free survival in early non‐metastatic prostate cancer: results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow‐up. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=752. McLeodDG , IversenP , SeeWA , MorrisT , ArmstrongJ , WirthMP . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU International2006;97(2):247‐54. McLeodDG , SeeWA , KlimbergI , GleasonD , ChodakG , MontieJ , et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7‐year median followup. Journal of Urology2006;176(1):75‐80. SeeW , IversenP , WirthM , McLeodD , GarsideL , MorrisT . Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology2003;44(5):512‐8. SeeWA , McLeodD , IversenP , WirthM . The bicalutamide Early Prostate Cancer Program: demography. Urologic Oncology2001;6(2):43‐7. SeeWA , McLeodDG , IversenP , WirthMP , ArmstrongJ , NavaniS . Effect of bicalutamide 150 mg on PSA progression in M0 prostate cancer: results from Early Prostate Cancer program. Journal of Clinical Oncology2006;24(18 Suppl):4624. SeeWA , TyrrellCJ . The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. Journal of Cancer Research and Clinical Oncology2006;132 Suppl 1:S7‐16. SeeWA , WirthMP , McLeodDG , IversenP , KlimbergI , GleasonD , et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. Journal of Urology2002;168(2):429‐35. TyrrellC . Immediate treatment with bicalutamide, 150 mg/d, following radiotherapy in localized or locally advanced prostate cancer. Reviews in Urology2004;6 Suppl 2:S29‐36. TyrrellCJ , PayneH , SeeWA , McLeodDG , WirthMP , IversenP , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiotherapy and Oncology2005;76(1):4‐10. WirthM , HakenbergO , FroehnerM . Adjuvant hormonal treatment ‐ the Bicalutamide Early Prostate Cancer Program. Frontiers of Radiation Therapy and Oncology2008;41:39‐48. WirthM , IversenP , McLeodD , SeeW , MorrisC , MorrisT , et al. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression‐free survival in patients with early non‐metastatic prostate cancer: analysis at a median follow‐up of 5.4 years. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=560. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceD , et al. Adjuvant therapy with bicalutamide 150 mg versus standard care alone: third analysis results from Trial 24 of the Early Prostate Cancer programme. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=9672. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double‐blind phase III study (median follow‐up 5.1 y) in the early prostate cancer programme. Prostate Cancer and Prostatic Diseases2005;8(2):194‐200. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide (Casodex) 150 mg plus standard care in early non‐metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow‐up. Prostate Cancer and Prostatic Diseases2007;10(1):87‐93. WirthM , TyrrellC , WallaceM , DelaereKP , Sánchez‐ChapadoM , RamonJ , et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology2001;58(2):146‐51. WirthMP , FroehnerM . Adjuvant hormonal treatment for prostate cancer: the Bicalutamide Early Prostate Cancer Program. Oncology2003;65 Suppl 1:1‐4. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , ArmstrongJ . Delaying metastatic disease progression in locally advanced disease ‐ results from the Early Prostate Cancer program at a median follow‐up of 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4629. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , CarrollK . Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. Journal of Urology2004;172(5 Pt 1):1865‐70. ">EPC program</a>; <a href="./references#CD009266-bbs2-0044" title="KotakeT , UsamiM , IsakaS , ShimazakiJ , NakanoE , OkuyamaA , et al. Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer. Hinyokika Kiyo. Acta Urologica Japonica1996;42(2):157‐68. ">Kotake 1996b</a>; <a href="./references#CD009266-bbs2-0054" title="LunglmayrG . Efficacy and tolerability of Casodex in patients with advanced prostate cancer. Anti‐cancer Drugs1995;6(4):508‐13. ">Lunglmayr 1995</a>; <a href="./references#CD009266-bbs2-0068" title="RainaR , PahalajaniG , AgarwalA , ZippeC . Long‐term effectiveness of luteinizing hormone‐releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1‐2): a retrospective study. Asian Journal of Andrology2007;9(2):253‐8. ">Raina 2007</a>; <a href="./references#CD009266-bbs2-0141" title="TyrrellCJ . Tolerability and quality of life aspects with the anti‐androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators. European Urology1994;26 Suppl 1:15‐9. ">Tyrrell 1994</a>; <a href="./references#CD009266-bbs2-0084" title="WadhwaV , WestonR , ParrNJ . Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health‐related quality of life benefits for osteoporotic men with prostate cancer. BJU International2011;107(12):1923‐9. ">Wadhwa 2011</a>), and hot flashes occurred in approximately 30% to 40% of these participants (<a href="./references#CD009266-bbs2-0095" title="BoccardoF , RubagottiA , BarichelloM , BattagliaM , CarmignaniG , ComeriG , et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. Journal of Clinical Oncology1999;17(7):2027‐38. ">Boccardo 1999</a>; <a href="./references#CD009266-bbs2-0030" title="FourcadeRO , RichaudP , BruneD , ColombelP , SarramonJP , FournierG , et al. Effect of bicalutamide 150 mg, after 3 years of median follow‐up, in non‐metastatic prostatic cancer [Effet du bicalutamide 150 mg, à trois ans de suivi médian, dans le cancer de la prostate non métastatique]. Progres en Urologie2003;13(3):430‐9. FourcadeRO , RichaudP , ColobyP , MalavaudB , Group des investigateuers français du programme EPC. Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program [Le bicalutamide 150 mg dans le traitement du cancer de la prostate localement avancé : des résultats à la pratique : Place du bicalutamide 150 mg dans le traitement du cancer de la prostate : hème analyse du programme EPC (Early Prostate Cancer)]. Progres en Urologie2007;17(4 Suppl 1):891‐910. IversenP , JohanssonJ‐E , LoddingP , LukkarinenO , LundmoPI , KlarskovP , et al. Efficacy and tolerability of bicalutamide in early non‐metastatic prostate cancer: Latest findings from the Scandinavian Prostatic Cancer Group Study No 6 (SPCG‐6) of the early prostate cancer programme. Meeting abstract of the 21st annual European Association of Urology Congress. 2006. www.uroweb.org/index.php?id=108&amp;AID=9715. IversenP , JohanssonJE , LoddingP , KylmalaT , LundmoP , KlarskovP , et al. Bicalutamide 150 mg in addition to standard care for patients with early non‐metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group‐6 Study after a median follow‐up period of 7.1 years. Scandinavian Journal of Urology and Nephrology2006;40(6):441‐52. IversenP , JohanssonJE , LoddingP , LukkarinenO , LundmoP , KlarskovP , et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3 year median followup from the Scandinavian Prostate Cancer Group Study Number 6. Journal of Urology2004;172(5 Pt 1):1871‐6. IversenP , McLeodD , SeeW , WirthM , MorrisT , MorrisC , et al. Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non‐metastatic prostate cancer: updated analysis at a median 5.4 years’ follow‐up. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=758. IversenP , McLeodDG , SeeWA , MorrisT , ArmstrongJ , WirthMP . Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years. BJU International2010;105(8):1074‐81. IversenP , RoderMA . The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Review of Anticancer Therapy2008;8(3):361‐9. IversenP , TammelaTLJ , VaageS , LukkarinenO , LoddingP , Bull‐NjaaT , et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non‐metastatic prostate cancer ‐ First report from the Scandinavian Prostatic Cancer Group Study No. 6. European Urology2002;42(3):204‐11. IversenP , WirthMP , SeeWAII , McLeodDG , MorrisT , ArmstrongJ , et al. The influence of nodal status on progression outcomes in patients with prostate cancer: data from the Early Prostate Cancer program at 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4628. IversenP , WirthMP , SeeWA , McLeodDG , KlimbergI , GleasonD , et al. Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology2004;63(5):928‐33. McLeodD , IversenP , SeeW , WirthM , CarrollK , MorrisC , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy significantly improves progression‐free survival in early non‐metastatic prostate cancer: results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow‐up. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=752. McLeodDG , IversenP , SeeWA , MorrisT , ArmstrongJ , WirthMP . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU International2006;97(2):247‐54. McLeodDG , SeeWA , KlimbergI , GleasonD , ChodakG , MontieJ , et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7‐year median followup. Journal of Urology2006;176(1):75‐80. SeeW , IversenP , WirthM , McLeodD , GarsideL , MorrisT . Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology2003;44(5):512‐8. SeeWA , McLeodD , IversenP , WirthM . The bicalutamide Early Prostate Cancer Program: demography. Urologic Oncology2001;6(2):43‐7. SeeWA , McLeodDG , IversenP , WirthMP , ArmstrongJ , NavaniS . Effect of bicalutamide 150 mg on PSA progression in M0 prostate cancer: results from Early Prostate Cancer program. Journal of Clinical Oncology2006;24(18 Suppl):4624. SeeWA , TyrrellCJ . The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. Journal of Cancer Research and Clinical Oncology2006;132 Suppl 1:S7‐16. SeeWA , WirthMP , McLeodDG , IversenP , KlimbergI , GleasonD , et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. Journal of Urology2002;168(2):429‐35. TyrrellC . Immediate treatment with bicalutamide, 150 mg/d, following radiotherapy in localized or locally advanced prostate cancer. Reviews in Urology2004;6 Suppl 2:S29‐36. TyrrellCJ , PayneH , SeeWA , McLeodDG , WirthMP , IversenP , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiotherapy and Oncology2005;76(1):4‐10. WirthM , HakenbergO , FroehnerM . Adjuvant hormonal treatment ‐ the Bicalutamide Early Prostate Cancer Program. Frontiers of Radiation Therapy and Oncology2008;41:39‐48. WirthM , IversenP , McLeodD , SeeW , MorrisC , MorrisT , et al. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression‐free survival in patients with early non‐metastatic prostate cancer: analysis at a median follow‐up of 5.4 years. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=560. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceD , et al. Adjuvant therapy with bicalutamide 150 mg versus standard care alone: third analysis results from Trial 24 of the Early Prostate Cancer programme. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=9672. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double‐blind phase III study (median follow‐up 5.1 y) in the early prostate cancer programme. Prostate Cancer and Prostatic Diseases2005;8(2):194‐200. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide (Casodex) 150 mg plus standard care in early non‐metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow‐up. Prostate Cancer and Prostatic Diseases2007;10(1):87‐93. WirthM , TyrrellC , WallaceM , DelaereKP , Sánchez‐ChapadoM , RamonJ , et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology2001;58(2):146‐51. WirthMP , FroehnerM . Adjuvant hormonal treatment for prostate cancer: the Bicalutamide Early Prostate Cancer Program. Oncology2003;65 Suppl 1:1‐4. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , ArmstrongJ . Delaying metastatic disease progression in locally advanced disease ‐ results from the Early Prostate Cancer program at a median follow‐up of 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4629. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , CarrollK . Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. Journal of Urology2004;172(5 Pt 1):1865‐70. ">EPC program</a>; <a href="./references#CD009266-bbs2-0054" title="LunglmayrG . Efficacy and tolerability of Casodex in patients with advanced prostate cancer. Anti‐cancer Drugs1995;6(4):508‐13. ">Lunglmayr 1995</a>). Results of studies evaluating non‐steroidal antiandrogens assume that the incidence of adverse events ranges between 40% and 74% (<a href="./references#CD009266-bbs2-0030" title="FourcadeRO , RichaudP , BruneD , ColombelP , SarramonJP , FournierG , et al. Effect of bicalutamide 150 mg, after 3 years of median follow‐up, in non‐metastatic prostatic cancer [Effet du bicalutamide 150 mg, à trois ans de suivi médian, dans le cancer de la prostate non métastatique]. Progres en Urologie2003;13(3):430‐9. FourcadeRO , RichaudP , ColobyP , MalavaudB , Group des investigateuers français du programme EPC. Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program [Le bicalutamide 150 mg dans le traitement du cancer de la prostate localement avancé : des résultats à la pratique : Place du bicalutamide 150 mg dans le traitement du cancer de la prostate : hème analyse du programme EPC (Early Prostate Cancer)]. Progres en Urologie2007;17(4 Suppl 1):891‐910. IversenP , JohanssonJ‐E , LoddingP , LukkarinenO , LundmoPI , KlarskovP , et al. Efficacy and tolerability of bicalutamide in early non‐metastatic prostate cancer: Latest findings from the Scandinavian Prostatic Cancer Group Study No 6 (SPCG‐6) of the early prostate cancer programme. Meeting abstract of the 21st annual European Association of Urology Congress. 2006. www.uroweb.org/index.php?id=108&amp;AID=9715. IversenP , JohanssonJE , LoddingP , KylmalaT , LundmoP , KlarskovP , et al. Bicalutamide 150 mg in addition to standard care for patients with early non‐metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group‐6 Study after a median follow‐up period of 7.1 years. Scandinavian Journal of Urology and Nephrology2006;40(6):441‐52. IversenP , JohanssonJE , LoddingP , LukkarinenO , LundmoP , KlarskovP , et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3 year median followup from the Scandinavian Prostate Cancer Group Study Number 6. Journal of Urology2004;172(5 Pt 1):1871‐6. IversenP , McLeodD , SeeW , WirthM , MorrisT , MorrisC , et al. Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non‐metastatic prostate cancer: updated analysis at a median 5.4 years’ follow‐up. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=758. IversenP , McLeodDG , SeeWA , MorrisT , ArmstrongJ , WirthMP . Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years. BJU International2010;105(8):1074‐81. IversenP , RoderMA . The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Review of Anticancer Therapy2008;8(3):361‐9. IversenP , TammelaTLJ , VaageS , LukkarinenO , LoddingP , Bull‐NjaaT , et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non‐metastatic prostate cancer ‐ First report from the Scandinavian Prostatic Cancer Group Study No. 6. European Urology2002;42(3):204‐11. IversenP , WirthMP , SeeWAII , McLeodDG , MorrisT , ArmstrongJ , et al. The influence of nodal status on progression outcomes in patients with prostate cancer: data from the Early Prostate Cancer program at 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4628. IversenP , WirthMP , SeeWA , McLeodDG , KlimbergI , GleasonD , et al. Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology2004;63(5):928‐33. McLeodD , IversenP , SeeW , WirthM , CarrollK , MorrisC , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy significantly improves progression‐free survival in early non‐metastatic prostate cancer: results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow‐up. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=752. McLeodDG , IversenP , SeeWA , MorrisT , ArmstrongJ , WirthMP . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU International2006;97(2):247‐54. McLeodDG , SeeWA , KlimbergI , GleasonD , ChodakG , MontieJ , et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7‐year median followup. Journal of Urology2006;176(1):75‐80. SeeW , IversenP , WirthM , McLeodD , GarsideL , MorrisT . Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology2003;44(5):512‐8. SeeWA , McLeodD , IversenP , WirthM . The bicalutamide Early Prostate Cancer Program: demography. Urologic Oncology2001;6(2):43‐7. SeeWA , McLeodDG , IversenP , WirthMP , ArmstrongJ , NavaniS . Effect of bicalutamide 150 mg on PSA progression in M0 prostate cancer: results from Early Prostate Cancer program. Journal of Clinical Oncology2006;24(18 Suppl):4624. SeeWA , TyrrellCJ . The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. Journal of Cancer Research and Clinical Oncology2006;132 Suppl 1:S7‐16. SeeWA , WirthMP , McLeodDG , IversenP , KlimbergI , GleasonD , et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. Journal of Urology2002;168(2):429‐35. TyrrellC . Immediate treatment with bicalutamide, 150 mg/d, following radiotherapy in localized or locally advanced prostate cancer. Reviews in Urology2004;6 Suppl 2:S29‐36. TyrrellCJ , PayneH , SeeWA , McLeodDG , WirthMP , IversenP , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiotherapy and Oncology2005;76(1):4‐10. WirthM , HakenbergO , FroehnerM . Adjuvant hormonal treatment ‐ the Bicalutamide Early Prostate Cancer Program. Frontiers of Radiation Therapy and Oncology2008;41:39‐48. WirthM , IversenP , McLeodD , SeeW , MorrisC , MorrisT , et al. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression‐free survival in patients with early non‐metastatic prostate cancer: analysis at a median follow‐up of 5.4 years. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=560. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceD , et al. Adjuvant therapy with bicalutamide 150 mg versus standard care alone: third analysis results from Trial 24 of the Early Prostate Cancer programme. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=9672. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double‐blind phase III study (median follow‐up 5.1 y) in the early prostate cancer programme. Prostate Cancer and Prostatic Diseases2005;8(2):194‐200. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide (Casodex) 150 mg plus standard care in early non‐metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow‐up. Prostate Cancer and Prostatic Diseases2007;10(1):87‐93. WirthM , TyrrellC , WallaceM , DelaereKP , Sánchez‐ChapadoM , RamonJ , et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology2001;58(2):146‐51. WirthMP , FroehnerM . Adjuvant hormonal treatment for prostate cancer: the Bicalutamide Early Prostate Cancer Program. Oncology2003;65 Suppl 1:1‐4. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , ArmstrongJ . Delaying metastatic disease progression in locally advanced disease ‐ results from the Early Prostate Cancer program at a median follow‐up of 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4629. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , CarrollK . Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. Journal of Urology2004;172(5 Pt 1):1865‐70. ">EPC program</a>; <a href="./references#CD009266-bbs2-0044" title="KotakeT , UsamiM , IsakaS , ShimazakiJ , NakanoE , OkuyamaA , et al. Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer. Hinyokika Kiyo. Acta Urologica Japonica1996;42(2):157‐68. ">Kotake 1996b</a>; <a href="./references#CD009266-bbs2-0068" title="RainaR , PahalajaniG , AgarwalA , ZippeC . Long‐term effectiveness of luteinizing hormone‐releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1‐2): a retrospective study. Asian Journal of Andrology2007;9(2):253‐8. ">Raina 2007</a>). Castration, on the other hand, increased adverse events such as hot flashes, haemorrhage, nocturia, urinary frequency, fatigue and loss of sexual interest, as indicated by this review. Side effects that have an impact on physiological and psychological health should be considered when androgen suppression therapies are prescribed because these effects can interfere with compliance as soon as the patient notices symptoms; thus, these patients might require additional treatment (<a href="./references#CD009266-bbs2-0121" title="KunathF , KeckB , AntesG , WullichB , MeerpohlJJ . Tamoxifen for the management of breast events induced by non‐steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Medicine2012;10:96. ">Kunath 2012</a>). </p> <p>Non‐steroidal antiandrogens lead to an increased rate of treatment discontinuation compared with castration because of their associated adverse events. This finding is consistent with the results of the systematic review published by Seidenfeld et al, as well as other studies, and accounts for 4% to 10% of patients receiving non‐steroidal antiandrogens (<a href="./references#CD009266-bbs2-0030" title="FourcadeRO , RichaudP , BruneD , ColombelP , SarramonJP , FournierG , et al. Effect of bicalutamide 150 mg, after 3 years of median follow‐up, in non‐metastatic prostatic cancer [Effet du bicalutamide 150 mg, à trois ans de suivi médian, dans le cancer de la prostate non métastatique]. Progres en Urologie2003;13(3):430‐9. FourcadeRO , RichaudP , ColobyP , MalavaudB , Group des investigateuers français du programme EPC. Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program [Le bicalutamide 150 mg dans le traitement du cancer de la prostate localement avancé : des résultats à la pratique : Place du bicalutamide 150 mg dans le traitement du cancer de la prostate : hème analyse du programme EPC (Early Prostate Cancer)]. Progres en Urologie2007;17(4 Suppl 1):891‐910. IversenP , JohanssonJ‐E , LoddingP , LukkarinenO , LundmoPI , KlarskovP , et al. Efficacy and tolerability of bicalutamide in early non‐metastatic prostate cancer: Latest findings from the Scandinavian Prostatic Cancer Group Study No 6 (SPCG‐6) of the early prostate cancer programme. Meeting abstract of the 21st annual European Association of Urology Congress. 2006. www.uroweb.org/index.php?id=108&amp;AID=9715. IversenP , JohanssonJE , LoddingP , KylmalaT , LundmoP , KlarskovP , et al. Bicalutamide 150 mg in addition to standard care for patients with early non‐metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group‐6 Study after a median follow‐up period of 7.1 years. Scandinavian Journal of Urology and Nephrology2006;40(6):441‐52. IversenP , JohanssonJE , LoddingP , LukkarinenO , LundmoP , KlarskovP , et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3 year median followup from the Scandinavian Prostate Cancer Group Study Number 6. Journal of Urology2004;172(5 Pt 1):1871‐6. IversenP , McLeodD , SeeW , WirthM , MorrisT , MorrisC , et al. Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non‐metastatic prostate cancer: updated analysis at a median 5.4 years’ follow‐up. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=758. IversenP , McLeodDG , SeeWA , MorrisT , ArmstrongJ , WirthMP . Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years. BJU International2010;105(8):1074‐81. IversenP , RoderMA . The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Review of Anticancer Therapy2008;8(3):361‐9. IversenP , TammelaTLJ , VaageS , LukkarinenO , LoddingP , Bull‐NjaaT , et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non‐metastatic prostate cancer ‐ First report from the Scandinavian Prostatic Cancer Group Study No. 6. European Urology2002;42(3):204‐11. IversenP , WirthMP , SeeWAII , McLeodDG , MorrisT , ArmstrongJ , et al. The influence of nodal status on progression outcomes in patients with prostate cancer: data from the Early Prostate Cancer program at 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4628. IversenP , WirthMP , SeeWA , McLeodDG , KlimbergI , GleasonD , et al. Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology2004;63(5):928‐33. McLeodD , IversenP , SeeW , WirthM , CarrollK , MorrisC , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy significantly improves progression‐free survival in early non‐metastatic prostate cancer: results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow‐up. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=752. McLeodDG , IversenP , SeeWA , MorrisT , ArmstrongJ , WirthMP . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU International2006;97(2):247‐54. McLeodDG , SeeWA , KlimbergI , GleasonD , ChodakG , MontieJ , et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7‐year median followup. Journal of Urology2006;176(1):75‐80. SeeW , IversenP , WirthM , McLeodD , GarsideL , MorrisT . Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology2003;44(5):512‐8. SeeWA , McLeodD , IversenP , WirthM . The bicalutamide Early Prostate Cancer Program: demography. Urologic Oncology2001;6(2):43‐7. SeeWA , McLeodDG , IversenP , WirthMP , ArmstrongJ , NavaniS . Effect of bicalutamide 150 mg on PSA progression in M0 prostate cancer: results from Early Prostate Cancer program. Journal of Clinical Oncology2006;24(18 Suppl):4624. SeeWA , TyrrellCJ . The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. Journal of Cancer Research and Clinical Oncology2006;132 Suppl 1:S7‐16. SeeWA , WirthMP , McLeodDG , IversenP , KlimbergI , GleasonD , et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. Journal of Urology2002;168(2):429‐35. TyrrellC . Immediate treatment with bicalutamide, 150 mg/d, following radiotherapy in localized or locally advanced prostate cancer. Reviews in Urology2004;6 Suppl 2:S29‐36. TyrrellCJ , PayneH , SeeWA , McLeodDG , WirthMP , IversenP , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiotherapy and Oncology2005;76(1):4‐10. WirthM , HakenbergO , FroehnerM . Adjuvant hormonal treatment ‐ the Bicalutamide Early Prostate Cancer Program. Frontiers of Radiation Therapy and Oncology2008;41:39‐48. WirthM , IversenP , McLeodD , SeeW , MorrisC , MorrisT , et al. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression‐free survival in patients with early non‐metastatic prostate cancer: analysis at a median follow‐up of 5.4 years. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=560. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceD , et al. Adjuvant therapy with bicalutamide 150 mg versus standard care alone: third analysis results from Trial 24 of the Early Prostate Cancer programme. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=9672. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double‐blind phase III study (median follow‐up 5.1 y) in the early prostate cancer programme. Prostate Cancer and Prostatic Diseases2005;8(2):194‐200. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide (Casodex) 150 mg plus standard care in early non‐metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow‐up. Prostate Cancer and Prostatic Diseases2007;10(1):87‐93. WirthM , TyrrellC , WallaceM , DelaereKP , Sánchez‐ChapadoM , RamonJ , et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology2001;58(2):146‐51. WirthMP , FroehnerM . Adjuvant hormonal treatment for prostate cancer: the Bicalutamide Early Prostate Cancer Program. Oncology2003;65 Suppl 1:1‐4. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , ArmstrongJ . Delaying metastatic disease progression in locally advanced disease ‐ results from the Early Prostate Cancer program at a median follow‐up of 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4629. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , CarrollK . Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. Journal of Urology2004;172(5 Pt 1):1865‐70. ">EPC program</a>; <a href="./references#CD009266-bbs2-0135" title="SeidenfeldJ , SamsonDJ , HasselbladV , AronsonN , AlbertsenPC , BennettCL , et al. Single‐therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta‐analysis. Annals of Internal Medicine2000;132(7):566‐77. ">Seidenfeld 2000</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0141" title="TyrrellCJ . Tolerability and quality of life aspects with the anti‐androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators. European Urology1994;26 Suppl 1:15‐9. ">Tyrrell 1994</a>). The main reasons for discontinuing treatment were elevated liver enzymes (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0141" title="TyrrellCJ . Tolerability and quality of life aspects with the anti‐androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators. European Urology1994;26 Suppl 1:15‐9. ">Tyrrell 1994</a>) and breast events (<a href="./references#CD009266-bbs2-0030" title="FourcadeRO , RichaudP , BruneD , ColombelP , SarramonJP , FournierG , et al. Effect of bicalutamide 150 mg, after 3 years of median follow‐up, in non‐metastatic prostatic cancer [Effet du bicalutamide 150 mg, à trois ans de suivi médian, dans le cancer de la prostate non métastatique]. Progres en Urologie2003;13(3):430‐9. FourcadeRO , RichaudP , ColobyP , MalavaudB , Group des investigateuers français du programme EPC. Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program [Le bicalutamide 150 mg dans le traitement du cancer de la prostate localement avancé : des résultats à la pratique : Place du bicalutamide 150 mg dans le traitement du cancer de la prostate : hème analyse du programme EPC (Early Prostate Cancer)]. Progres en Urologie2007;17(4 Suppl 1):891‐910. IversenP , JohanssonJ‐E , LoddingP , LukkarinenO , LundmoPI , KlarskovP , et al. Efficacy and tolerability of bicalutamide in early non‐metastatic prostate cancer: Latest findings from the Scandinavian Prostatic Cancer Group Study No 6 (SPCG‐6) of the early prostate cancer programme. Meeting abstract of the 21st annual European Association of Urology Congress. 2006. www.uroweb.org/index.php?id=108&amp;AID=9715. IversenP , JohanssonJE , LoddingP , KylmalaT , LundmoP , KlarskovP , et al. Bicalutamide 150 mg in addition to standard care for patients with early non‐metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group‐6 Study after a median follow‐up period of 7.1 years. Scandinavian Journal of Urology and Nephrology2006;40(6):441‐52. IversenP , JohanssonJE , LoddingP , LukkarinenO , LundmoP , KlarskovP , et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3 year median followup from the Scandinavian Prostate Cancer Group Study Number 6. Journal of Urology2004;172(5 Pt 1):1871‐6. IversenP , McLeodD , SeeW , WirthM , MorrisT , MorrisC , et al. Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non‐metastatic prostate cancer: updated analysis at a median 5.4 years’ follow‐up. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=758. IversenP , McLeodDG , SeeWA , MorrisT , ArmstrongJ , WirthMP . Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years. BJU International2010;105(8):1074‐81. IversenP , RoderMA . The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Review of Anticancer Therapy2008;8(3):361‐9. IversenP , TammelaTLJ , VaageS , LukkarinenO , LoddingP , Bull‐NjaaT , et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non‐metastatic prostate cancer ‐ First report from the Scandinavian Prostatic Cancer Group Study No. 6. European Urology2002;42(3):204‐11. IversenP , WirthMP , SeeWAII , McLeodDG , MorrisT , ArmstrongJ , et al. The influence of nodal status on progression outcomes in patients with prostate cancer: data from the Early Prostate Cancer program at 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4628. IversenP , WirthMP , SeeWA , McLeodDG , KlimbergI , GleasonD , et al. Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology2004;63(5):928‐33. McLeodD , IversenP , SeeW , WirthM , CarrollK , MorrisC , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy significantly improves progression‐free survival in early non‐metastatic prostate cancer: results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow‐up. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=752. McLeodDG , IversenP , SeeWA , MorrisT , ArmstrongJ , WirthMP . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU International2006;97(2):247‐54. McLeodDG , SeeWA , KlimbergI , GleasonD , ChodakG , MontieJ , et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7‐year median followup. Journal of Urology2006;176(1):75‐80. SeeW , IversenP , WirthM , McLeodD , GarsideL , MorrisT . Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology2003;44(5):512‐8. SeeWA , McLeodD , IversenP , WirthM . The bicalutamide Early Prostate Cancer Program: demography. Urologic Oncology2001;6(2):43‐7. SeeWA , McLeodDG , IversenP , WirthMP , ArmstrongJ , NavaniS . Effect of bicalutamide 150 mg on PSA progression in M0 prostate cancer: results from Early Prostate Cancer program. Journal of Clinical Oncology2006;24(18 Suppl):4624. SeeWA , TyrrellCJ . The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. Journal of Cancer Research and Clinical Oncology2006;132 Suppl 1:S7‐16. SeeWA , WirthMP , McLeodDG , IversenP , KlimbergI , GleasonD , et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. Journal of Urology2002;168(2):429‐35. TyrrellC . Immediate treatment with bicalutamide, 150 mg/d, following radiotherapy in localized or locally advanced prostate cancer. Reviews in Urology2004;6 Suppl 2:S29‐36. TyrrellCJ , PayneH , SeeWA , McLeodDG , WirthMP , IversenP , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiotherapy and Oncology2005;76(1):4‐10. WirthM , HakenbergO , FroehnerM . Adjuvant hormonal treatment ‐ the Bicalutamide Early Prostate Cancer Program. Frontiers of Radiation Therapy and Oncology2008;41:39‐48. WirthM , IversenP , McLeodD , SeeW , MorrisC , MorrisT , et al. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression‐free survival in patients with early non‐metastatic prostate cancer: analysis at a median follow‐up of 5.4 years. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=560. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceD , et al. Adjuvant therapy with bicalutamide 150 mg versus standard care alone: third analysis results from Trial 24 of the Early Prostate Cancer programme. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=9672. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double‐blind phase III study (median follow‐up 5.1 y) in the early prostate cancer programme. Prostate Cancer and Prostatic Diseases2005;8(2):194‐200. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide (Casodex) 150 mg plus standard care in early non‐metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow‐up. Prostate Cancer and Prostatic Diseases2007;10(1):87‐93. WirthM , TyrrellC , WallaceM , DelaereKP , Sánchez‐ChapadoM , RamonJ , et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology2001;58(2):146‐51. WirthMP , FroehnerM . Adjuvant hormonal treatment for prostate cancer: the Bicalutamide Early Prostate Cancer Program. Oncology2003;65 Suppl 1:1‐4. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , ArmstrongJ . Delaying metastatic disease progression in locally advanced disease ‐ results from the Early Prostate Cancer program at a median follow‐up of 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4629. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , CarrollK . Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. Journal of Urology2004;172(5 Pt 1):1865‐70. ">EPC program</a>). </p> <p>We found no data on the impact of androgen suppression therapy on cardiovascular events. However, androgen suppression might adversely affect cardiovascular risk (<a href="./references#CD009266-bbs2-0100" title="DockeryF , BulpittCJ , AgarwalS , RajkumarC . Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness. Aging Male2002;5(4):216‐22. ">Dockery 2002</a>; <a href="./references#CD009266-bbs2-0002" title="DockeryF , BulpittCJ , AgarwalS , VernonC , NihoyannopoulosP , KempM , et al. Anti‐androgens increase N‐Terminal pro‐BNP in men with prostate cancer. Clinical Endocrinology2008;68:59‐65. DockeryF , BulpittCJ , AgarwalS , VernonC , RajkumarC . Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology2009;30(4):410‐5. ">Dockery 2009</a>), and men with existing cardiovascular disease might have increased mortality (<a href="./references#CD009266-bbs2-0103" title="EfstathiouJA , BaeK , ShipleyWU , HanksGE , PilepichMV , SandlerHM , et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85‐31. Journal of Clinical Oncology2009;27(1):92‐9. ">Efstathiou 2009</a>). However, adjuvant castration does not appear to increase cardiovascular mortality in men with advanced prostate cancer who do not have notable cardiovascular risk (<a href="./references#CD009266-bbs2-0102" title="EfstathiouJA , BaeK , ShipleyWU , HanksGE , PilepichMV , SandlerHM , et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92‐02. European Urology2008;54(4):816‐23. ">Efstathiou 2008</a>; <a href="./references#CD009266-bbs2-0124" title="NguyenPL , JeY , SchutzFAB , HoffmanKE , HuJC , ParekhA , et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta‐analysis of randomized trials. JAMA2011;306(21):2359‐66. ">Nguyen 2011</a>). </p> <p>In the included studies, bicalutamide was the most frequently assessed non‐steroidal antiandrogen. Only one study (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>) with a small sample size evaluated flutamide; we identified no studies evaluating nilutamide. This observation is consistent with common prescribing practices. A recent study evaluated men registered in the National Prostate Cancer Register of Sweden to determine the prescribing patterns of therapy with bicalutamide (<a href="./references#CD009266-bbs2-0109" title="GrundmarkB , GarmoH , ZetheliusB , StattinP , LambeM , HolmbergL . Anti‐androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. European Journal of Clinical Pharmacology2012;68(12):1619‐30. ">Grundmark 2012</a>). Of the 58,143 patients with prostate cancer registered in the National Prostate Cancer Register of Sweden, 4.4% (n = 2558) were treated with non‐steroidal antiandrogens and 1406 received bicalutamide monotherapy. Of these, 79% received a dosage of 150 mg per day. The prescription of other antiandrogens was very rare (n = 88) (<a href="./references#CD009266-bbs2-0109" title="GrundmarkB , GarmoH , ZetheliusB , StattinP , LambeM , HolmbergL . Anti‐androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. European Journal of Clinical Pharmacology2012;68(12):1619‐30. ">Grundmark 2012</a>). </p> <p>We did not include studies that compared non‐steroidal antiandrogens with placebo. Evidence from large randomised controlled trials suggests that non‐steroidal antiandrogens (bicalutamide at 150 mg daily) given as an adjuvant to radiotherapy significantly improve progression‐free survival compared with radiotherapy alone. However, these studies showed no significant differences in overall survival after 9.7 years (<a href="./references#CD009266-bbs2-0030" title="FourcadeRO , RichaudP , BruneD , ColombelP , SarramonJP , FournierG , et al. Effect of bicalutamide 150 mg, after 3 years of median follow‐up, in non‐metastatic prostatic cancer [Effet du bicalutamide 150 mg, à trois ans de suivi médian, dans le cancer de la prostate non métastatique]. Progres en Urologie2003;13(3):430‐9. FourcadeRO , RichaudP , ColobyP , MalavaudB , Group des investigateuers français du programme EPC. Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program [Le bicalutamide 150 mg dans le traitement du cancer de la prostate localement avancé : des résultats à la pratique : Place du bicalutamide 150 mg dans le traitement du cancer de la prostate : hème analyse du programme EPC (Early Prostate Cancer)]. Progres en Urologie2007;17(4 Suppl 1):891‐910. IversenP , JohanssonJ‐E , LoddingP , LukkarinenO , LundmoPI , KlarskovP , et al. Efficacy and tolerability of bicalutamide in early non‐metastatic prostate cancer: Latest findings from the Scandinavian Prostatic Cancer Group Study No 6 (SPCG‐6) of the early prostate cancer programme. Meeting abstract of the 21st annual European Association of Urology Congress. 2006. www.uroweb.org/index.php?id=108&amp;AID=9715. IversenP , JohanssonJE , LoddingP , KylmalaT , LundmoP , KlarskovP , et al. Bicalutamide 150 mg in addition to standard care for patients with early non‐metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group‐6 Study after a median follow‐up period of 7.1 years. Scandinavian Journal of Urology and Nephrology2006;40(6):441‐52. IversenP , JohanssonJE , LoddingP , LukkarinenO , LundmoP , KlarskovP , et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3 year median followup from the Scandinavian Prostate Cancer Group Study Number 6. Journal of Urology2004;172(5 Pt 1):1871‐6. IversenP , McLeodD , SeeW , WirthM , MorrisT , MorrisC , et al. Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non‐metastatic prostate cancer: updated analysis at a median 5.4 years’ follow‐up. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=758. IversenP , McLeodDG , SeeWA , MorrisT , ArmstrongJ , WirthMP . Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years. BJU International2010;105(8):1074‐81. IversenP , RoderMA . The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Review of Anticancer Therapy2008;8(3):361‐9. IversenP , TammelaTLJ , VaageS , LukkarinenO , LoddingP , Bull‐NjaaT , et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non‐metastatic prostate cancer ‐ First report from the Scandinavian Prostatic Cancer Group Study No. 6. European Urology2002;42(3):204‐11. IversenP , WirthMP , SeeWAII , McLeodDG , MorrisT , ArmstrongJ , et al. The influence of nodal status on progression outcomes in patients with prostate cancer: data from the Early Prostate Cancer program at 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4628. IversenP , WirthMP , SeeWA , McLeodDG , KlimbergI , GleasonD , et al. Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology2004;63(5):928‐33. McLeodD , IversenP , SeeW , WirthM , CarrollK , MorrisC , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy significantly improves progression‐free survival in early non‐metastatic prostate cancer: results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow‐up. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=752. McLeodDG , IversenP , SeeWA , MorrisT , ArmstrongJ , WirthMP . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU International2006;97(2):247‐54. McLeodDG , SeeWA , KlimbergI , GleasonD , ChodakG , MontieJ , et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7‐year median followup. Journal of Urology2006;176(1):75‐80. SeeW , IversenP , WirthM , McLeodD , GarsideL , MorrisT . Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology2003;44(5):512‐8. SeeWA , McLeodD , IversenP , WirthM . The bicalutamide Early Prostate Cancer Program: demography. Urologic Oncology2001;6(2):43‐7. SeeWA , McLeodDG , IversenP , WirthMP , ArmstrongJ , NavaniS . Effect of bicalutamide 150 mg on PSA progression in M0 prostate cancer: results from Early Prostate Cancer program. Journal of Clinical Oncology2006;24(18 Suppl):4624. SeeWA , TyrrellCJ . The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. Journal of Cancer Research and Clinical Oncology2006;132 Suppl 1:S7‐16. SeeWA , WirthMP , McLeodDG , IversenP , KlimbergI , GleasonD , et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. Journal of Urology2002;168(2):429‐35. TyrrellC . Immediate treatment with bicalutamide, 150 mg/d, following radiotherapy in localized or locally advanced prostate cancer. Reviews in Urology2004;6 Suppl 2:S29‐36. TyrrellCJ , PayneH , SeeWA , McLeodDG , WirthMP , IversenP , et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiotherapy and Oncology2005;76(1):4‐10. WirthM , HakenbergO , FroehnerM . Adjuvant hormonal treatment ‐ the Bicalutamide Early Prostate Cancer Program. Frontiers of Radiation Therapy and Oncology2008;41:39‐48. WirthM , IversenP , McLeodD , SeeW , MorrisC , MorrisT , et al. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression‐free survival in patients with early non‐metastatic prostate cancer: analysis at a median follow‐up of 5.4 years. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=560. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceD , et al. Adjuvant therapy with bicalutamide 150 mg versus standard care alone: third analysis results from Trial 24 of the Early Prostate Cancer programme. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&amp;AID=9672. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double‐blind phase III study (median follow‐up 5.1 y) in the early prostate cancer programme. Prostate Cancer and Prostatic Diseases2005;8(2):194‐200. WirthM , TyrrellC , DelaereK , Sanchez‐ChapadoM , RamonJ , WallaceDM , et al. Bicalutamide (Casodex) 150 mg plus standard care in early non‐metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow‐up. Prostate Cancer and Prostatic Diseases2007;10(1):87‐93. WirthM , TyrrellC , WallaceM , DelaereKP , Sánchez‐ChapadoM , RamonJ , et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology2001;58(2):146‐51. WirthMP , FroehnerM . Adjuvant hormonal treatment for prostate cancer: the Bicalutamide Early Prostate Cancer Program. Oncology2003;65 Suppl 1:1‐4. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , ArmstrongJ . Delaying metastatic disease progression in locally advanced disease ‐ results from the Early Prostate Cancer program at a median follow‐up of 7.4 years. Journal of Clinical Oncology2006;24(18 Suppl):4629. WirthMP , SeeWA , McLeodDG , IversenP , MorrisT , CarrollK . Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. Journal of Urology2004;172(5 Pt 1):1865‐70. ">EPC program</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009266-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (searched 26 February 2013; updated 23 December 2013)." data-id="CD009266-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (searched 26 February 2013; updated 23 December 2013).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot: Outcome: 1.1 Overall survival, 1.1.1 Total." data-id="CD009266-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Funnel plot: Outcome: 1.1 Overall survival, 1.1.1 Total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009266-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 1 Overall survival." data-id="CD009266-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 2 Cancer‐specific mortality." data-id="CD009266-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 2 Cancer‐specific mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 3 Treatment discontinuation due to adverse events." data-id="CD009266-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 3 Treatment discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 4 Clinical progression." data-id="CD009266-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 4 Clinical progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 5 Clinical progression (with imputed event numbers)." data-id="CD009266-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 5 Clinical progression (with imputed event numbers). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 6 Biochemical progression." data-id="CD009266-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 6 Biochemical progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 7 Biochemical progression (with imputed event numbers)." data-id="CD009266-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 7 Biochemical progression (with imputed event numbers). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 8 Treatment failure." data-id="CD009266-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 8 Treatment failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 9 Treatment failure (with imputed event numbers)." data-id="CD009266-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 9 Treatment failure (with imputed event numbers). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 10 Breast pain." data-id="CD009266-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 10 Breast pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 11 Pelvic pain." data-id="CD009266-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 11 Pelvic pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 12 Bone pain." data-id="CD009266-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 12 Bone pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 13 Back pain." data-id="CD009266-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 13 Back pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 14 Headache." data-id="CD009266-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 14 Headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 15 Abdominal pain." data-id="CD009266-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 15 Abdominal pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 16 General pain." data-id="CD009266-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 16 General pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 17 Gynaecomastia." data-id="CD009266-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 17 Gynaecomastia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 18 Constipation." data-id="CD009266-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 18 Constipation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 19 Diarrhoea." data-id="CD009266-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 19 Diarrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 20 Vomiting." data-id="CD009266-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 20 Vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 21 Hypertension." data-id="CD009266-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 21 Hypertension. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 22 Loss of sexual interest." data-id="CD009266-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 22 Loss of sexual interest. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 23 Asthenia." data-id="CD009266-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 23 Asthenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 24 Insomnia." data-id="CD009266-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 24 Insomnia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 25 Hot flashes." data-id="CD009266-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 25 Hot flashes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 26 Night sweats." data-id="CD009266-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 26 Night sweats. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 27 Anaemia." data-id="CD009266-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 27 Anaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 28 Hepatic enzyme increase." data-id="CD009266-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 28 Hepatic enzyme increase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 29 Rash." data-id="CD009266-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 29 Rash. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 30 Pruritus." data-id="CD009266-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 30 Pruritus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 31 Dyspnoea." data-id="CD009266-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 31 Dyspnoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 32 Infection." data-id="CD009266-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 32 Infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 33 Pharyngitis." data-id="CD009266-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 33 Pharyngitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 34 Arthritis." data-id="CD009266-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 34 Arthritis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 35 Sinusitis." data-id="CD009266-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 35 Sinusitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 36 Urinary tract infection." data-id="CD009266-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 36 Urinary tract infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 37 Dizziness." data-id="CD009266-fig-0040" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 37 Dizziness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 38 Haemorrhage." data-id="CD009266-fig-0041" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 38 Haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 39 Haematuria." data-id="CD009266-fig-0042" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 39 Haematuria. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 40 Nocturia." data-id="CD009266-fig-0043" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 40 Nocturia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 41 Urinary frequency." data-id="CD009266-fig-0044" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 41 Urinary frequency. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 42 Urinary retention." data-id="CD009266-fig-0045" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 42 Urinary retention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 43 Peripheral oedema." data-id="CD009266-fig-0046" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 43 Peripheral oedema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 44 Anorexia." data-id="CD009266-fig-0047" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 44 Anorexia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 45 Loss of sexual function." data-id="CD009266-fig-0048" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 45 Loss of sexual function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 46 Arthralgia." data-id="CD009266-fig-0049" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 46 Arthralgia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 47 Gastralgia." data-id="CD009266-fig-0050" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 47 Gastralgia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 48 Nausea." data-id="CD009266-fig-0051" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 48 Nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-49" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-49.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 49 Fatigue." data-id="CD009266-fig-0052" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-49.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.49</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 49 Fatigue. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-49.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-50" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-50.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 50 Dry skin." data-id="CD009266-fig-0053" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-50.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.50</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 50 Dry skin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-50.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-51" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-51.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 51 Aggravation reaction." data-id="CD009266-fig-0054" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-51.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.51</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 51 Aggravation reaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-51.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009266-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/urn:x-wiley:14651858:media:CD009266:CD009266-CMP-001-52" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_t/tCD009266-CMP-001-52.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 52 Serious adverse events." data-id="CD009266-fig-0055" src="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-52.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.52</div> <div class="figure-caption"> <p>Comparison 1 Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy, Outcome 52 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/media/CDSR/CD009266/image_n/nCD009266-CMP-001-52.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009266-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy for advanced prostate cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy for advanced prostate cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> men with advanced prostate cancer<br/> <b>Settings:</b> multi‐centre (9 studies) and single‐centre studies (2 studies) on outpatients<br/> <b>Intervention:</b> non‐steroidal antiandrogen monotherapy </p> <p><b>Comparison:</b> LHRH agonists or surgical castration monotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Hazard ratio/ Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Castration</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Non‐steroidal antiandrogen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> <br/> Follow‐up: median 1 to 6.3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>353 per 1000</b> <br/> (308 to 405) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.24</b> <br/> (1.05 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2712<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival was evaluated using the random‐effects model because of heterogeneity (I<sup>2</sup> = 51%). Sensitivity analyses showed comparable results. Numbers of absolute risks relate to deaths </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical progression</b> <br/> Follow‐up: median 70 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>529 per 1000</b> <br/> (453 to 608) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/> (1.08 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2373<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical progression after median 70 weeks was evaluated using the random‐effects model because of heterogeneity (I<sup>2</sup> = 64%). Sensitivity analyses showed comparable results. After imputation of event numbers: RR 1.43, 95% CI 1.19 to 1.73, I<sup>2</sup> = 0%; fixed‐effect model </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> <br/> Follow‐up: median 70 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>527 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>669 per 1000</b> <br/> (553 to 801) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.27</b> <br/> (1.05 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1845<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure after median 70 weeks was evaluated using the random‐effects model because of heterogeneity (I<sup>2</sup> = 81%). Sensitivity analyses showed comparable results. After imputation of event numbers: RR 1.21, 95% CI 1.09 to 1.35, I<sup>2</sup> = 0%; fixed‐effect model </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breast pain</b> <br/> Follow‐up: median 1 to 6.3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>397 per 1000</b> <br/> (256 to 617) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 22.97</b> <br/> (14.79 to 35.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2670<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Breast pain was evaluated using the fixed‐effect model (I<sup>2</sup> = 0%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gynaecomastia</b> <br/> Follow‐up: median 1 to 6.3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b> <br/> (142 to 989) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.43</b> <br/> (3.19 to 22.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2774<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gynaecomastia was evaluated using the random‐effects model because of heterogeneity (I<sup>2</sup> = 92%). Sensitivity analyses showed comparable results </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hot flashes</b> <br/> Follow‐up: median 1 to 6.3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> <br/> (86 to 122) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.23</b> <br/> (0.19 to 0.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2774<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hot flashes were evaluated using the fixed‐effect model (I<sup>2</sup> = 0%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>LHRH:</b> Luteinising hormone‐releasing hormone; <b>CI:</b> Confidence interval; <b>HR:</b> Hazard ratio; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for study limitations (‐1): high risk of bias: 'allocation concealment' (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); unclear risk of bias: 'random sequence generation' (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'allocation concealment' (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301;</a><a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'blinding of participants and personnel' (all included studies); 'other bias' (all included studies).<br/> <sup>2</sup>Downgraded for study limitations (‐1): high risk of bias: 'blinding of participants and personnel' (all included studies); 'blinding of outcome assessment' (all included studies); 'incomplete outcome data' (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301;</a><a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302;</a><a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>); 'selective reporting' (<a href="./references#CD009266-bbs2-0003" title="SciarraA , DiSilverioF . Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology2004;63(3):523‐7. ">Sciarra 2004a</a>); unclear risk of bias: 'random sequence generation' (all included studies); 'allocation concealment' (all included studies); 'other bias' (all included studies).<br/> <sup>3</sup>Downgraded for study limitations (‐1): high risk of bias: 'blinding of participants and personnel' (all included studies); 'blinding of outcome assessment' (all included studies); 'incomplete outcome data' (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301;</a><a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302;</a><a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>); unclear risk of bias: 'random sequence generation' (all included studies); 'allocation concealment' (all included studies); 'other bias' (all included studies).<br/> <sup>4</sup>Downgraded for study limitations (‐1): high risk of bias: 'allocation concealment' (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'blinding of participants and personnel' (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004;</a><a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301;</a><a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302;</a><a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'blinding of outcome assessment' (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'incomplete outcome data' (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>); unclear risk of bias: 'random sequence generation' (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'allocation concealment' (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'blinding of participants and personnel' (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>); 'blinding of outcome assessment' (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>); 'other bias' (all included studies).<br/> <sup>5</sup>Downgraded for study limitations (‐1): high risk of bias: 'allocation concealment' (<a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'blinding of participants and personnel' (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'blinding of outcome assessment' (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>; <a href="./references#CD009266-bbs2-0011" title="TyrrellCJ , IversenP , TammelaT , AndersonJ , BjorkT , KaisaryAV , et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International2005;96(3):563‐72. Erratum in: BJU International 2006;98(3):572. ">Tyrrell 2006</a>); 'incomplete outcome data' (<a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>); unclear risk of bias: 'random sequence generation' (<a href="./references#CD009266-bbs2-0001" title="Boccon‐GibodL , FournierG , BottetP , MarechalJM , GuiterJ , RischmanP , et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology1997;32(4):391‐5; discussion 5‐6. ">Boccon‐Gibod 1997</a>; <a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'allocation concealment' (<a href="./references#CD009266-bbs2-0004" title="SieberPR , KeillerDL , KahnoskiRJ , GalloJ , McFaddenS . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology2004;171(6 Pt 1):2272‐6. ">Sieber 2004</a>; <a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>; <a href="./references#CD009266-bbs2-0006" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. IversenP , TveterK , VarenhorstE . Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology1996;30(2):93‐8. ">Study 0301</a>; <a href="./references#CD009266-bbs2-0007" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. KaisaryAV , TyrrellCJ , BeacockC , LunglmayrG , DebruyneF . A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology1995;28(3):215‐22. ">Study 0302</a>; <a href="./references#CD009266-bbs2-0008" title="BalesGT , ChodakGW . A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology1996;47(1A Suppl):38‐43; discussion 48‐53. ChodakG , SharifiR , KasimisB , BlockNL , MacramallaE , KennealeyGT . Single‐agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology1995;46(6):849‐55. ">Study 0303</a>; <a href="./references#CD009266-bbs2-0009" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 306</a>; <a href="./references#CD009266-bbs2-0010" title="IversenP , TyrrellCJ , KaisaryAV , AndersonJB , BaertL , TammelaT , et al. Casodex (bicalutamide) 150‐mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow‐up of 4 years. Urology1998;51(3):389‐96. IversenP , TyrrellCJ , KaisaryAV , AndersonJB , VanPoppelH , TammelaTL , et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology2000;164(5):1579‐82. TyrrellCJ , BlakeGM , IversenP , KaisaryAV , MelezinekI . The non‐steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology2003;21(1):37‐42. TyrrellCJ , KaisaryAV , IversenP , AndersonJB , BaertL , TammelaT , et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology1998;33(5):447‐56. ">Study 307</a>); 'blinding of participants and personnel' (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>); 'blinding of outcome assessment' (<a href="./references#CD009266-bbs2-0005" title="PirlWF , GreerJA , GoodeM , SmithMR . Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho‐oncology2008;17(2):148‐53. SmithMR , GoodeM , ZietmanAL , McGovernFJ , LeeH , FinkelsteinJS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology2004;22(13):2546‐53. ">Smith 2004</a>); 'other bias' (all included studies).<br/> <sup>6</sup>Heterogeneity was present but might be explained by subgroup or sensitivity analyses (see <a href="#CD009266-sec-0083">Effects of interventions</a>; <a href="#CD009266-sec-0108">Quality of the evidence</a>); therefore we did not downgrade for inconsistency. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy for advanced prostate cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/full#CD009266-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009266-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.05, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Subgroup analysis: non‐metastatic disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Subgroup analysis: metastatic disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.14, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.19, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.96, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Subgroup analysis: bicalutamide 450 mg daily or 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.62, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Subgroup analysis: non‐metastatic disease and bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.81, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Subgroup analysis: non‐metastatic disease and bicalutamide 450 mg daily or 600 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.46, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 Subgroup analysis: metastatic disease and bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.19, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 Subgroup analysis: metastatic disease and bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.04, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11 Subgroup analysis: metastatic disease and bicalutamide 450 mg daily or 600 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.56, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cancer‐specific mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.86, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Total after a minimum 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.71, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Total after median 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.73, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.13, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Subgroup analysis: non‐metastatic disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.66, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Subgroup analysis: metastatic disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.54, 3.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.29, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.66, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Subgroup analysis: flutamide 250 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.35 [0.46, 151.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [1.17, 6.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.95, 6.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Total at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.08, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Total at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.08, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Total at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.04, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Total at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.87, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Total at 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.91, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Total at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Subgroup analysis: non‐metastatic disease at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.82, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Subgroup analysis: non‐metastatic disease at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.83, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Subgroup analysis: non‐metastatic disease at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.81, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 Subgroup analysis: non‐metastatic disease at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.87, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11 Subgroup analysis: non‐metastatic disease at 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.91, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12 Subgroup analysis: non‐metastatic disease at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.88, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13 Subgroup analysis: metastatic disease at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.05, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14 Subgroup analysis: metastatic disease at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.07, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15 Subgroup analysis: metastatic disease at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.05, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16 Subgroup analysis: bicalutamide 50 mg daily at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.91, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.17 Subgroup analysis: bicalutamide 50 mg daily at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.99, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.18 Subgroup analysis: bicalutamide 150 mg daily at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.07, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.19 Subgroup analysis: bicalutamide 150 mg daily at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.07, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.20 Subgroup analysis: bicalutamide 150 mg daily at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.04, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.21 Subgroup analysis: bicalutamide 150 mg daily at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.87, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.22 Subgroup analysis: bicalutamide 150 mg daily at 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.91, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.23 Subgroup analysis: bicalutamide 150 mg daily at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.88, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.24 Subgroup analysis: bicalutamide 450 mg daily at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.54, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.25 Subgroup analysis: bicalutamide 600 mg daily at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.33, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinical progression (with imputed event numbers) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Total (with imputed event numbers) at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.16, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Total (with imputed event numbers) at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.19, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Total (with imputed event numbers) at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.09, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Total (with imputed event numbers) at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.56, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Subgroup analysis: non‐metastatic disease (with imputed event numbers) at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.80, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Subgroup analysis: non‐metastatic disease (with imputed event numbers) at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.78, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Subgroup analysis: non‐metastatic disease (with imputed event numbers) at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.71, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Subgroup analysis: non‐metastatic disease (with imputed event numbers) at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.52, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 Subgroup analysis: metastatic disease (with imputed event numbers) at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.16, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 Subgroup analysis: metastatic disease (with imputed event numbers) at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.20, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11 Subgroup analysis: metastatic disease (with imputed event numbers) at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.22, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.12 Subgroup analysis: bicalutamide 50 mg daily (with imputed event numbers) at 1 year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.99, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.13 Subgroup analysis: bicalutamide 50 mg daily (with imputed event numbers) at 70 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.04, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.14 Subgroup analysis: bicalutamide 150 mg daily (with imputed event numbers) at 1 year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.12, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.15 Subgroup analysis: bicalutamide 150 mg daily (with imputed event numbers) at 70 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.14, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16 Subgroup analysis: bicalutamide 150 mg daily (with imputed event numbers) at 2 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.09, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.17 Subgroup analysis: bicalutamide 150 mg daily (with imputed event numbers) at 5 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.52, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.18 Subgroup analysis: bicalutamide 450 mg daily (with imputed event numbers) at 5 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.41, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.19 Subgroup analysis: bicalutamide 600 mg daily (with imputed event numbers) at 5 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.27, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Biochemical progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Total at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.13, 73.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Total at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Total at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.94, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Biochemical progression (with imputed event numbers) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Total (with imputed event numbers) at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [0.15, 34.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Total (with imputed event numbers) at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.00, 196.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Total (with imputed event numbers) at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.72, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Total at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.02, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Total at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.05, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Total at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.05, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Total at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.63, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Total at 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.93, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Subgroup analysis: non‐metastatic disease at 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.93, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Subgroup analysis: metastatic disease at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.02, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 Subgroup analysis: metastatic disease at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.05, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 Subgroup analysis: metastatic disease at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.05, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 Subgroup analysis: metastatic disease at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.63, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.11 Subgroup analysis: bicalutamide 50 mg daily at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.90, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.12 Subgroup analysis: bicalutamide 50 mg daily at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.98, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.13 Subgroup analysis: bicalutamide 150 mg daily at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.01, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.14 Subgroup analysis: bicalutamide 150 mg daily at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.05, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.15 Subgroup analysis: bicalutamide 150 mg daily at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.05, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.16 Subgroup analysis: bicalutamide 150 mg daily at 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.93, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.17 Subgroup analysis: flutamide 250 mg 3 times daily at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.63, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Treatment failure (with imputed event numbers) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Total (with imputed event numbers) at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.06, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Total (with imputed event numbers) at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.09, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Total (with imputed event numbers) at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.32, 7.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Subgroup analysis: metastatic disease (with imputed event numbers) at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.06, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Subgroup analysis: metastatic disease (with imputed event numbers) at 70 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.09, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 Subgroup analysis: metastatic disease (with imputed event numbers) at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.32, 7.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 Subgroup analysis: bicalutamide 50 mg daily (with imputed event numbers) at 1 year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.01, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 Subgroup analysis: bicalutamide 50 mg daily (with imputed event numbers) at 70 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.05, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9 Subgroup analysis: bicalutamide 150 mg daily (with imputed event numbers) at 1 year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.01, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.10 Subgroup analysis: bicalutamide 150 mg daily (with imputed event numbers) at 70 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.05, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.11 Subgroup analysis: flutamide 250 mg 3 times daily (with imputed event numbers) at 3 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.32, 7.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Breast pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.97 [14.79, 35.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.39 [10.26, 36.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.82 [13.34, 49.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.48 [5.88, 93.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.71 [6.37, 103.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Pelvic pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.78, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.64, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.79, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Bone pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.68, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Back pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.70, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.54, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.54, 7.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.59, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.29, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.24, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.20, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Subgroup analysis: flutamide 250 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [0.12, 66.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.90, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.58, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.92, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Subgroup analysis: flutamide 250 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 General pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.65, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.71, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.80, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.67, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Gynaecomastia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.43 [3.19, 22.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.07 [3.74, 52.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.01 [0.88, 28.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 Subgroup analysis: flutamide 250 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [1.33, 10.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>27.88 [7.02, 110.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.6 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.36 [4.97, 83.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.65, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.50, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.84, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.03, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.80, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.00, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.14, 12.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 Subgroup analysis: flutamide 250 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.35 [0.46, 151.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.5 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.57, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.6 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [0.86, 5.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.88 [1.38, 10.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.99, 9.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Subgroup analysis: flutamide 250 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.2 [0.58, 179.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.06, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Loss of sexual interest <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.30, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Asthenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.36, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.11, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.10, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [1.38, 6.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.5 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.95, 6.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.11, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.02, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.38, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.4 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.29, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Hot flashes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.19, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.15, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.19, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.4 Subgroup analysis: flutamide 250 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.10, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.5 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.12, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.6 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.15, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Night sweats <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.17, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.12, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.14, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.16, 5.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [0.34, 30.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.31, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Hepatic enzyme increase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.91 [0.59, 40.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.14 [0.38, 134.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.3 Subgroup analysis: flutamide 250 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [0.12, 66.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.77, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.50, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.10 [0.62, 42.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.4 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.47, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.5 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.58, 5.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.93, 7.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.93, 7.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Dyspnoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 Bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.24, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.58, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.34, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.65, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Pharyngitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.47, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.11, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.56, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.4 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.34, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Arthritis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 Bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.12, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Sinusitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 Bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.36, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Urinary tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.53, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.43, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.3 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.40, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.4 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.57, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.61, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.49, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.49, 4.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.01, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.01, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Haematuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.14, 9.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.26, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.49 [2.01, 6.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Nocturia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 Bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.20, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Urinary frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 Bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.11, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Urinary retention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 Bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.55, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.33, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.21, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.3 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.54, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 Anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1 Bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.57, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 Loss of sexual function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.1 Bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.14, 6.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 Arthralgia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.86, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.2 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.01, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.3 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.36, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 Gastralgia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.1 Flutamide 250 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [0.12, 66.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [0.95, 11.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.2 Subgroup analysis: bicalutamide 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [0.95, 11.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1 Bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.31, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50 Dry skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.41 [0.42, 132.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.2 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.81 [0.48, 161.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.3 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.35 [0.26, 152.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51 Aggravation reaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.1 Bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.45, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.2 Subgroup analysis: bicalutamide 150 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.49, 4.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.3 Subgroup analysis: bicalutamide 450 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.73, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.4 Subgroup analysis: bicalutamide 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.71, 1.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009266.pub2/references#CD009266-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009266.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009266-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009266-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009266-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD009266-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009266-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009266\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009266\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009266\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009266\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009266\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009266.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009266.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009266.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009266.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009266.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725795945"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009266.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725795949"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009266.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e83f1acd2936d',t:'MTc0MDcyNTc5Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 